WO2021112398A1 - Composition comprising vitamin c - Google Patents

Composition comprising vitamin c Download PDF

Info

Publication number
WO2021112398A1
WO2021112398A1 PCT/KR2020/014311 KR2020014311W WO2021112398A1 WO 2021112398 A1 WO2021112398 A1 WO 2021112398A1 KR 2020014311 W KR2020014311 W KR 2020014311W WO 2021112398 A1 WO2021112398 A1 WO 2021112398A1
Authority
WO
WIPO (PCT)
Prior art keywords
present
vitamin
cosmetic composition
oils
fats
Prior art date
Application number
PCT/KR2020/014311
Other languages
French (fr)
Korean (ko)
Inventor
전영선
Original Assignee
(주)이시스코스메틱
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)이시스코스메틱 filed Critical (주)이시스코스메틱
Publication of WO2021112398A1 publication Critical patent/WO2021112398A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers

Definitions

  • the present invention relates to a stable composition comprising vitamin C.
  • the adverse effects on the skin can be divided into internal factors and external factors.
  • internal factors free radicals generated by stress are mentioned, and the external factors include excessive UV exposure due to environmental pollution.
  • Vitamin C acts as a powerful biological antioxidant in the skin, blood and other tissues, and has a sugar-like structure that accepts two electrons and is easily oxidized to the form of dehydro-L-ascorbic acid (Dehydro-L-ascorbic acid). ) to prevent oxidation or denaturation of biocomponents such as proteins by highly reactive free radicals and peroxides in the living body.
  • vitamin C has a pigmentation inhibitory effect, which is achieved by inhibiting the production of melanin, which is closely related to pigmentation.
  • Vitamin C inhibits the activity of tyrosinase, which is important for the formation of melanin, and reduces the oxidized melanin formed by the oxidation process and changes it into reduced melanin, thereby improving the pigmentation symptoms caused by melanin.
  • the cosmetic composition containing vitamin C has the above useful effects, it is easily oxidized by air, moisture, light, heat, metal ions, oxygen, base, etc. to 2,3-diketo-L-gulonic acid (2 ,3-diketo-L-gulonic acid), oxalic acid, L-threonic acid, L-xylonic acid, L-Lyxonic acid, etc. is oxidized to At this time, there is a big problem in stability and safety in the formulation, such as a drop in potency and discoloration and odor. In addition, it is common that a large amount of pure vitamin C has a poor feeling of use and irritation, and precipitation occurs.
  • An object of the present invention is to provide a composition having high stability of vitamin C, less skin irritation, and excellent skin whitening effect.
  • Another object of the present invention is to provide a method for preparing a vitamin C-containing composition.
  • one or more stabilizers selected from the group consisting of lemon myrtle extract, fullerene and oils and fats were included.
  • the present invention is a first invention.
  • At least one stabilizer selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats
  • composition comprising a.
  • the cosmetic composition of the present invention can be used for skin whitening by the effect of vitamin C.
  • the cosmetic composition may include two or more stabilizers selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats as stabilizers.
  • the cosmetic composition may include lemon myrtle extract and fullerene as stabilizers.
  • the cosmetic composition may include lemon myrtle extract, fullerene and oils and fats as stabilizers.
  • vitamin C included in the cosmetic composition may be pure ascorbic acid.
  • the oils and fats included in the cosmetic composition may be at least one selected from the group consisting of hydrocarbons, silicones, oil-soluble vitamin derivatives, and ester oils.
  • the hydrocarbon may be a C 18-21 alkane.
  • the content of vitamin C may be 30 w/v% or less, preferably 1 to 20 w/v%.
  • the content of oils and fats may be 1 to 20 w/v%.
  • the cosmetic composition may be a functional cosmetic for skin whitening.
  • the present invention is a first invention.
  • At least one stabilizer selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats
  • composition for whitening comprising a.
  • the present invention provides a method for preparing a composition comprising vitamin C, comprising the step of preparing a mixture by mixing vitamin C, lemon myrtle extract and fullerene in an aqueous solvent.
  • the composition of the present invention has high vitamin C stability. Therefore, the composition of the present invention has excellent storage stability and can stably maintain the effect of vitamin C for a long period of time. In addition, the composition of the present invention can ensure stability even when it contains a large amount of vitamin C.
  • composition of the present invention is less irritating when applied to the skin. Therefore, the composition of the present invention can be used without discomfort even for sensitive or weak skin.
  • composition of the present invention exhibits skin whitening, wrinkle improvement, elasticity improvement and antioxidant action. Therefore, it can be usefully used as a cosmetic and pharmaceutical composition.
  • the cosmetic composition of the present invention comprises: (i) vitamin C; and (ii) at least one stabilizing agent.
  • the stabilizer may be at least one selected from the group consisting of lemon myrtle extract, fullerene, and oils and fats.
  • vitamin C means ascorbic acid having the structure of the following formula (I) or a derivative thereof, or a salt or solvate thereof.
  • vitamin C may be pure ascorbic acid.
  • pure ascorbic acid means that the content of the compound of the structure [Formula I], which is not a derivative of ascorbic acid, is 90% or more, preferably 95% or more, more preferably 99% or more with respect to the total vitamin C. .
  • Vitamin C prevents the production of melanin and whitens the skin, and helps to synthesize collagen that makes up the skin, thereby improving wrinkles and improving elasticity. In addition, it also exhibits an antioxidant effect that suppresses free radicals generated due to pollution such as ultraviolet rays and fine dust, and stress.
  • vitamin C is a sensitive substance that is easily destroyed by heat, light, water, and oxygen, it is important to maintain its stability.
  • the cosmetic composition of the present invention has very excellent vitamin C stability, it can effectively exhibit skin whitening, wrinkle improvement, elasticity improvement, and antioxidant effects.
  • lemon myrtle is a plant of the family Myrtaceae, and the scientific name is Backhousia citriodora , lemon scented myrtle, lemon scented ironwood, sweet verbena. It is also called sweet verbena tree, sweet verbena myrtle, lemon scented verbena, lemon scented backhousia, etc. Lemon myrtle is native to the subtropical rain forests of central and southeastern Queensland, Australia.
  • extract includes all substances obtained by extracting the components of a natural product, regardless of the extraction method, extraction solvent, extracted component or the form of the extract, and extracting the material obtained by extracting the component of the natural product It is a broad concept that includes all substances that can be obtained by further processing or processing in other ways.
  • processing or treatment may be, for example, additional fermentation or enzymatic treatment of the extract.
  • an extract is a fraction, an extract or a crude product or purified product of a fraction, or a dilution, concentrate, dried product, fermented product, or mixture thereof, and the like, including extracts of all formulations formable from lemon myrtle. to be.
  • the “lemon myrtle extract” may be an extract of the whole herb, which is the leaf, flower, root, stem, fruit, or a combination thereof, of lemon myrtle, and may be an extract of a part or all of the above-ground part or root part of the herb; Preferably, it may be an extract of lemon myrtle whole plant, and more preferably, it may be an extract of lemon myrtle leaves.
  • the lemon myrtle extract may be prepared using a general preparation method known in the art, and is not particularly limited.
  • a general preparation method known in the art for example, ultrasonic extraction method, supercritical extraction method, vacuum extraction method reflux extraction method, hot water extraction method, low temperature hot water extraction method, high temperature pressure extraction method, low temperature high pressure extraction method, ultra high pressure extraction method, enzyme extraction method, solvent extraction method, cold extraction method, steam distillation method, low temperature high pressure distillation method, It may be prepared by a known method using an elution method, a compression method, a heat extraction method, or an extraction solvent, but is not limited thereto.
  • the lemon myrtle extract may be obtained by low-temperature high-pressure distillation.
  • the lemon myrtle extract may be prepared as an extract using water, an organic solvent, or a mixture thereof as an extraction solvent.
  • the water may include, for example, distilled water, purified water, or sterile water, but is not limited thereto.
  • the organic solvent may include, for example, alcohol, glycerin, butylene glycol, propylene glycol, methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane, but is not limited thereto.
  • the lemon myrtle extract is preferably extracted with a solvent selected from the group consisting of water, C 1-6 alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, and mixtures thereof. It may be extracted with a solvent.
  • the concentration of the C 1-6 alcohol may be 10% to 90%, preferably 30% to 90%, and more preferably 50% to 90%.
  • the lemon myrtle extract of the present invention may be purchased commercially, or may be prepared by the known extraction method described above, and preferably extracted in distilled water at low temperature.
  • the lemon myrtle extract may be lemon myrtle distilled water.
  • the lemon myrtle extract can effectively prevent the decomposition and oxidation of vitamin C by external environments such as moisture, temperature, and air by increasing the internal oxidation stability of vitamin C.
  • “Fullerene” is an allotrope of carbon consisting of 60 carbon atoms of the structure of the following [Formula II], and is a carbon-bonded structure having a stable structure that is formed like a soccer ball.
  • Fullerene has insulation, organic solvent solubility, thermal stability, thermal decomposition inhibition, and antioxidant properties, and by utilizing these properties, its application is continuously reviewed in many fields such as magnetic materials, optical materials, superconducting materials, medical care, secondary batteries, and lubricants. is becoming
  • fullerene can effectively prevent decomposition and oxidation of vitamin C by external environments such as moisture, temperature, and air by increasing the internal oxidation stability of vitamin C.
  • oils and fats refer to substances that may exist in the oil phase when the solution is divided into an oil phase and an aqueous phase.
  • oils and fats may include, for example, hydrocarbons, silicones, oil-soluble vitamin derivatives, or ester oils.
  • the cosmetic composition of the present invention may include one or more oils and fats selected from the group consisting of hydrocarbons, silicones, oil-soluble vitamin derivatives, and ester oils.
  • oils and fats effectively prevent decomposition and oxidation by external environments such as moisture, temperature, and air by capturing and stabilizing vitamin C in the inner layer of the water-in-oil dispersion formulation, and the stickiness and slipping phenomenon of vitamin C It is possible to secure stability by using a mechanism to block oxygen on the surface.
  • oils and fats act as a protective agent that prevents contact between vitamin C and external air, thereby preventing oxidation of an aqueous solution in which vitamin C, preferably vitamin C, is dissolved from external oxidizing factors.
  • the hydrocarbon may be a straight-chain or branched alkane, alkene, or alkyne, preferably a C 12-25 alkane, more preferably a C 18-21 alkane.
  • the silicon is a polymer of an organosilicon compound, and refers to a polymer containing silicon as a main component.
  • the oil-soluble vitamin derivative is a vitamin soluble in fat, and includes vitamins A, D, E, and K or derivatives thereof, for example, tocopherol and tocopheryl acetate tocotrienol.
  • the stabilizer may be two or more selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats.
  • the present invention provides a cosmetic composition comprising a lemon myrtle extract and fullerene, a cosmetic composition comprising a lemon myrtle extract and oils and fats, a cosmetic composition comprising a fullerene and fats and oils, or a cosmetic comprising a lemon myrtle extract, fullerene and oils and fats. It may be a composition.
  • the cosmetic composition may include only fullerene as a stabilizer, and may further include a lemon myrtle extract.
  • the cosmetic composition includes lemon myrtle extract, fullerene and oils and fats as stabilizers.
  • the cosmetic composition of the present invention may further include an additional active ingredient functional as a cosmetic in addition to vitamin C.
  • the cosmetic composition of the present invention may further include additional active ingredients effective for whitening, wrinkle improvement, moisturizing, exfoliation, elasticity improvement, antioxidant or oil control, and the like.
  • the cosmetic composition of the present invention may further include vitamin A or vitamin D.
  • the vitamin A and vitamin D have various skin improvement effects including whitening.
  • vitamin A and vitamin D are fat-soluble vitamins, they may also function as stabilizers in the cosmetic composition of the present invention.
  • the content of vitamin C is 50 w/v% or less, preferably 30 w/v% or less, more preferably 20 w/v% or less.
  • the content of vitamin C may be 0.1 w/v% or more, preferably 1 w/v% or more, more preferably 10 w/v% or more.
  • the content of vitamin C may be 10 to 20 w / v%.
  • the content of the lemon myrtle extract may be 90 w/v% or less, preferably 80 w/v% or less, and more preferably 70 w/v% or less.
  • the content of the lemon myrtle extract may be 0.1 w/v% or more, preferably 5 w/v% or more, and more preferably 10 w/v% or more.
  • the content of the lemon myrtle extract may be 10 to 70 w / v%.
  • the content of fullerene may be 5 ppm or less, preferably 3 ppm or less, more preferably 2 ppm or less.
  • the content of fullerene may be 0.01 ppm or more, preferably 0.1 ppm or more, more preferably 1.0 ppm or more.
  • the content of fullerene may be 1.0 to 2 ppm.
  • the content of fullerene may be 0.0005 w/v% or less, preferably 0.0003 w/v% or less, and more preferably 0.0002 w/v% or less.
  • the content of fullerene may be 0.000001 w/v% or more, preferably 0.00001 w/v% or more, and more preferably 0.0001 w/v% or more.
  • the content of fullerene may be 0.0001 w/v% to 0.0002 w/v%.
  • the content of oils and fats may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less.
  • the content of oils and fats may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of oils and fats may be 1 to 20 w/v%.
  • the content of C 18-21 alkane may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less.
  • the content of C 18-21 alkane may be 0.1 w/v% or more, more preferably 1 w/v% or more.
  • the content of C 18-21 alkane may be 1 to 20 w/v%.
  • the content of silicone may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less.
  • the content of silicone may be 0.1 w/v% or more, more preferably 1 w/v% or more.
  • the content of silicone may be 1 to 20 w/v%.
  • the content of the oil-soluble vitamin derivative is 50 w/v% or less, preferably 30 w/v% or less, more preferably 20 w/v% or less.
  • the content of the oil-soluble vitamin derivative may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of the oil-soluble vitamin derivative may be 1 to 20 w/v%.
  • the content of the ester oil may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less.
  • the content of the ester oil may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of ester oil may be 1 to 20 w/v%.
  • the cosmetic composition of the present invention is particularly effective and excellent in whitening, and can be used as a functional cosmetic for skin whitening.
  • the cosmetic composition of the present invention also has excellent anti-wrinkle effect, and can be used as a functional cosmetic for wrinkle improvement.
  • the cosmetic composition of the present invention exhibits excellent stability and can be stored for a long time without decreasing the titer of vitamin C.
  • the cosmetic composition of the present invention exhibits excellent stability at 40° C. or less. Specifically, it was confirmed that the cosmetic composition of the present invention exhibits excellent stability at 5°C. In addition, it was confirmed that the cosmetic composition of the present invention exhibits excellent stability at 25°C. Furthermore, it was confirmed that the cosmetic composition of the present invention exhibits excellent stability at 40°C. Accordingly, the cosmetic composition of the present invention exhibits excellent stability at 5°C to 40°C, 5 to 30°C, or 5 to 25°C.
  • the cosmetic composition of the present invention contains at least one selected from the group consisting of lemon myrtle extract, fullerene, and oil and fat as a stabilizer, skin irritation does not occur and excellent skin whitening effect is maintained.
  • the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing It may be formulated as cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, a pack, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a spray, or a powder.
  • a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing It may be formulated as cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, a pack, an eye cream
  • the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, bentonite, silica, talc, or zinc oxide is used as a carrier component.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder, etc. may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluoro propellants such as hydrocarbons, propane/butane or dimethyl ether.
  • a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzo Eight, propylene glycol, butylene glycol, 1,3-butyl glycol oil, polyoxyethylene hydrogenated castor oil, glycerol, glycerin, aliphatic ester, phenoxyethanol, triethanolamine, polyethylene glycol, beeswax, polysorbate 60, sorbitan Sesquioride, Paraffin, Sorbitan Stearate, Lipophilic Monostearate Glycerin, Stearic Acid, Glyceryl Stearate/PEG-400 Stearate, Carboxypolymer, Sitosterol, Polyglyceryl 2-oleate, Ceramide, Cholesterol , steareth-4
  • a solvent, solubilizer or emulsifier is used as
  • a liquid diluent such as water, ethanol, butylene glycol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • Suspending agents such as, microcrystalline cellulose, hydroxyethyl cellulose, sodium hyaluronate, phenoxyethanol, aluminum metahydroxide, bentonite, agar or tracanth may be used.
  • the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing
  • fatty acid amide ether sulfate, alkylamidobetaine fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like
  • the cosmetic composition of the present invention may include a cosmetically acceptable additive, for example, may include one or more additives selected from solubilizers, thickeners and surfactants.
  • the cosmetic composition of the present invention may include a solubilizer and a thickener.
  • the solubilizer is, for example, polyglyceryl-10 laurate, polyglyceryl-4 laurate, octyldodeses-16yl, PEG-40 hydrogenated pizza oil, PEG-1-PEG-9 lauryl glygol ethers, C 12-13 pareth 9, heptyl glucose and sorbitan oleate.
  • the solubilizing agent may be at least one selected from polyglyceryl-10 laurate, polyglyceryl-4 laurate, and octyldodeses-16yl.
  • the cosmetic composition of the present invention may include polyglyceryl-10 laurate, polyglyceryl-4 laurate and octyldodeses-16 as solubilizers.
  • the thickener is, for example, hydrophilic silica, polysaccharide, alginate, xanthan gum, carbomer, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethylpropylcellulose, hydroxypropylcellulose, polyethylene glycol ester, polyacrylate, poly acrylamide, polyvinyl alcohol, polyvinylpyrrolidone, cyclopentasiloxane, disteadimo hectoride, propylene carbonate, kaolin, calamine, smectide clay, and the like, but is not limited thereto.
  • the thickening agent may be hydroxyethylcellulose.
  • the pharmaceutical composition of the present invention comprises: (i) vitamin C; and (ii) at least one stabilizer.
  • the stabilizer may be at least one selected from the group consisting of lemon myrtle extract, fullerene, and oils and fats.
  • vitamin C in the pharmaceutical composition of the present invention, the description of vitamin C, lemon myrtle extract, fullerene, and oils and fats is the same as described above in the cosmetic composition.
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier in a range that does not impair the effects of the present invention.
  • the type of pharmaceutically acceptable carrier that can be used in the present invention is not particularly limited, and any carrier commonly used in the art may be used.
  • the carrier may include, for example, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, and the like. , but is not limited thereto.
  • the carrier may be used alone or as a mixture of two or more.
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive in a range that does not impair the effects of the present invention.
  • a pharmaceutically acceptable additive in a range that does not impair the effects of the present invention.
  • the types of pharmaceutically acceptable additives that can be used in the present invention are not particularly limited, and any additives commonly used in the art may be used.
  • the additives may include, but are not limited to, fillers, binders, disintegrants, suspending agents, solvents, antioxidants, pH adjusting agents, wetting agents, sweetening agents and preservatives, for example.
  • the above additives may be used alone or in combination of two or more.
  • compositions of the present invention may be in various formulations suitable for oral or parenteral administration.
  • formulations for oral administration include, for example, tablets, pills, powders, powders, granules, pellets, capsules, troches, lozenges, suspensions, emulsions, syrups and elixirs.
  • formulations for parenteral administration include, for example, injections, suppositories, respiratory inhalants, aerosols, ointments, powders for application, oils, creams and gels, but are not limited thereto.
  • parenteral administration includes, for example, intraperitoneal administration, rectal administration, subcutaneous administration, intravenous administration, intramuscular administration, chest administration, cerebrovascular administration and transdermal administration and hair administration, and the composition is applied to the diseased site or spraying or inhaling, but is not limited thereto.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of an effective amount includes the patient's condition, weight, sex, age, health Condition, severity of disease, sensitivity to drug, administration time, route of administration, rate of excretion, duration of treatment, factors including concomitant drugs and other factors well known in the medical field.
  • the dosage of the pharmaceutical composition of the present invention may be appropriately selected by those skilled in the art.
  • the dosage of the pharmaceutical composition of the present invention may be 0.1 mg/kg to 2,000 mg/kg per day, more preferably 1 mg/kg to 500 mg/kg, based on the content of the extract of the middle head extract.
  • the present invention is not limited thereto. In addition, it does not limit the scope of the present invention of the above dosage.
  • Administration of the pharmaceutical composition of the present invention may be administered once a day, may be administered in several divided doses, may be administered once every several days.
  • the administration period of the pharmaceutical composition of the present invention is well known to those skilled in the art by those skilled in the art that the patient's condition, weight, sex, age, health condition, degree of disease, sensitivity to drugs, factors including concurrent drugs, and other medical fields are well known. factors can be taken into account.
  • the pharmaceutical composition of the present invention may be administered alone or in combination with other therapeutic agents, and may be administered simultaneously or sequentially with other therapeutic agents.
  • the pharmaceutical composition of the present invention may be used in combination with surgery, hormone therapy, chemotherapy, and methods using biological response modifiers.
  • a composition containing vitamin C including the step of preparing a mixture by mixing vitamin C, lemon myrtle extract and fullerene in an aqueous solvent.
  • vitamin C comprising the steps of (a) mixing vitamin C, lemon myrtle extract and fullerene in an aqueous solvent to prepare a mixture, and (b) filling the mixture with oils and fats; compositions can be prepared.
  • step (a) after mixing the oil and fat with other fat-soluble ingredients, it may be peeled together with the mixture of step (a).
  • the oils and fats after the oils and fats are mixed with tocopherol, beta-carotene or both, it may be filled with the mixture of step (a).
  • Example 1 (w/v %)
  • Example 2 (w/v %)
  • Example 3 (w/v %)
  • Example 4 (w/v %)
  • Example 5 (w/v %)
  • Purified water to.100 to.100 to.100 to.100 Lemon Myrtle Distilled Water - 10 30 50 70 fullerene 0.00015 0.00015 0.00015 0.00015 ascorbic acid 15 15 15 15 15 15
  • Octyldodeces-16 0.15 0.15 0.15 0.15 0.15 hydroxyethyl cellulose 0.4 0.4 0.4 0.4 0.4 0.4
  • Purified water, ascorbic acid, distilled lemon myrtle water, fullerene, solubilizers (polyglyceryl-10 laurate, polyglyceryl-4 laurate, octyldodeses-16) and thickening agents (hydroxyethylcellulose) are listed below [Table 2] ] (first mixture).
  • solubilizers polyglyceryl-10 laurate, polyglyceryl-4 laurate, octyldodeses-16
  • thickening agents hydroxyethylcellulose
  • Example 6 (w/v %) Example 7 (w/v %) Example 8 (w/v %) Example 9 (w/v %) Example 10 (w/v %) Example 11 (w/v %) Example 12 (w/v %) Example 13 (w/v %) Purified water to.100 to.100 to.100 to.100 to.100 to.100 to.100 Lemon Myrtle Distilled Water 50 50 50 50 50 50 50 50 50 50 50 fullerene 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 ascorbic acid 15 15 15 15 15 10 14 18 Polyglyceryl-10 Laurate 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Polyglyceryl-4 Laurate 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Octyldodeces-16 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 hydroxyethyl cellulose 0.4 0.4 0.4 0.4 0.4 0.4
  • Examples 14 to 21 were prepared according to the contents described in [Table 3] in the same manner as in Examples 6 to 13.
  • Example 14 (w/v %) Example 15 (w/v %) Example 16 (w/v %) Example 17 (w/v %) Example 18 (w/v %) Example 19 (w/v %) Example 20 (w/v %) Example 21 (w/v %) Purified water to.100 to.100 to.100 to.100 to.100 to.100 to.100 Lemon Myrtle Distilled Water 50 50 50 50 50 50 50 50 50 50 50 50 50 fullerene 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 ascorbic acid 15 15 15 15 15 10 14 18 Polyglyceryl-10 Laurate 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Polyglyceryl-4 Laurate 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Octyldodeces-16 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 hydroxyethyl cellulose 0.4 0.4 0.4 0.4 0.4
  • Examples 22 to 29 were prepared according to the contents described in [Table 4] in the same manner as in Examples 6 to 13.
  • Example 22 (w/v %) Example 23 (w/v %) Example 24 (w/v %) Example 25 (w/v %) Example 26 (w/v %) Example 27 (w/v %) Example 28 (w/v %) Example 29 (w/v %) Purified water to.100 to.100 to.100 to.100 to.100 to.100 Lemon Myrtle Distilled Water 50 50 50 50 50 50 50 50 50 50 50 50 fullerene 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 0.00015 ascorbic acid 15 15 15 15 15 10 14 18 Polyglyceryl-10 Laurate 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Polyglyceryl-4 Laurate 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Octyldodeces-16 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 hydroxyethyl cellulose 0.4 0.4 0.4 0.4 0.4 0.4 0.4
  • Examples 30 to 37 were prepared according to the contents described in [Table 5] in the same manner as in Examples 6 to 13.
  • Comparative Example 1 (w/v %) Comparative Example 2 (w/v %) Comparative Example 3 (w/v %) Comparative Example 4 (w/v %) Purified water to.100 to.100 to.100 Lemon Myrtle Distilled Water - 70 50 - fullerene - - - - ascorbic acid 15 15 15 15 15 Polyglyceryl-10 Laurate 0.15 0.15 0.15 0.15 Polyglyceryl-4 Laurate 0.15 0.15 0.15 0.15 Octyldodeces-16 0.15 0.15 0.15 0.15 0.15 hydroxyethyl cellulose 0.4 0.4 0.4 0.4 C 18-21 Alkane - - 10 10 tocopherol - - 0.1 0.1 beta-carotene - - 0.1 0.1
  • Comparative Examples 1 and 2 were prepared in the same manner as in Examples 1 to 5, and Comparative Examples 3 and 4 in the same manner as in Examples 6 to 13, according to the contents described in Table 6 below.
  • Comparative Example 1 (w/v %) Comparative Example 2 (w/v %) Comparative Example 3 (w/v %) Comparative Example 4 (w/v %) Purified water to.100 to.100 to.100 Lemon Myrtle Distilled Water - 70 50 - fullerene - - - - ascorbic acid 15 15 15 15 15 Polyglyceryl-10 Laurate 0.15 0.15 0.15 0.15 Polyglyceryl-4 Laurate 0.15 0.15 0.15 0.15 Octyldodeces-16 0.15 0.15 0.15 0.15 0.15 hydroxyethyl cellulose 0.4 0.4 0.4 0.4 C 18-21 Alkane - - 10 10 tocopherol - - 0.1 0.1 beta-carotene - - 0.1 0.1
  • Example 1 Example 2
  • Example 3 Example 4
  • Example 5 Example 6
  • Example 7 Early 100% 100% 100% 100% 100% 100% 100% 100% 100% 1 month later 5°C 98.20% 97.10% 98.10% 97.20% 98.20% 98.3 97.5 25°C 95.20% 96.50% 97.30% 97.90% 95.20% 97.4 98.8
  • Example 8 Example 9 Example 10 Example 11 Example 12 Example 13 Early 100% 100% 100% 100% 100% 100% 100% 100% 1 month later 5°C 98.4 99.2 94.5 94.8 93.4 94.1 25°C 97.6 98.8 96.8 93.7 92.1 95.4
  • Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Early 100% 100% 100% 100% 100% 1 month later 5°C 88.5% 92.80% 87.5 84.2 25°C 65.10% 75.20% 94.4 90.2
  • Example 6 Example 7
  • Example 8 Example 9
  • Example 10 Example 11
  • Example 12 Example 13 Early 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 1 month later 40°C 93.4% 91.1% 92.4% 94.4% 90.8% 93.6% 94.6% 92.5%
  • Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Early 100% 100% 100% 100% 100% 1 month later 40°C 50.5% 61.5% 68.8% 64.8%
  • Example 11 At the first visit, after wiping the test site with 70% ethanol and drying, 15 ⁇ l of the cosmetic composition of Example 11, Example 12 or Example 13 was applied to the back of the subject in a Finn chamber and fixed with plaster.
  • the skin reaction of the test site was visually assessed by a dermatologist 30 minutes after the patch was removed.
  • the skin reaction of the test site was visually evaluated by a dermatologist.
  • the stimulation index was calculated by calculating the scores of the subjects determined at the 2nd, 3rd and 4th visits according to Equation 1 below.
  • the cosmetic composition of Example 11 had a stimulation index of 0.016
  • the cosmetic composition of Example 12 had a stimulation index of 0.021
  • the cosmetic composition of Example 13 had a stimulation index of 0.016, and all were determined to be non-irritating.
  • Example 11 At visit 1, the cosmetic composition of Example 11, Example 12 or Example 13 was applied to the face. Then, facial pictures were taken using a VISIA®CR (Canfield, USA). One of the hyperpigmented lesions on the left and right sides of the facial area was found and marked on the photograph, and the melanin level (M-value) was measured using Mexameter® MX 18 (CK electronic GmbH, Germany).
  • Example 11 At visit 2 (two weeks after visit 1) and visit 3 (after 4 weeks from visit 1), the cosmetic composition of Example 11, Example 12 or Example 13 was applied as in the 1st visit. Then, facial photography was performed using VISIA®CR. Melanin levels in hyperpigmented lesions were measured with Mexameter® MX 18 at the same site as indicated at Visit 1.
  • a dermatologist evaluated the presence or absence of adverse reactions (irritating symptoms such as pruritus and erythema), and no special skin abnormalities occurred during the test period.
  • the degree of improvement in hyperpigmentation was calculated by calculating the melanin level measured at the first visit, the second visit and the third visit by Equation 2 below, and the results are shown in Table 14.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a cosmetic composition comprising: (i) vitamin C; and (ii) at least one kind of stabilizing agent selected from the group consisting of a lemon myrtle extract, fullerenes, and oil and fats. The composition of the present invention has a high stability of vitamin C. Thus, the composition of the present invention has excellent storage stability and thus can stably retain effects of vitamin C for a long period. In addition, the composition of the present invention can secure stability even when a large amount of vitamin C is contained.

Description

비타민 C를 포함하는 조성물Compositions comprising vitamin C
본 발명은 비타민 C를 포함하는 안정한 조성물에 대한 것이다.The present invention relates to a stable composition comprising vitamin C.
피부에 악영향을 미치는 영향은 내부요인과 외부요인으로 나눌 수 있는데, 내부요인 중에서는 스트레스로 발생하는 자유 라디칼을 들 수 있으며, 외부 요인으로는 환경오염으로 인한 과도한 자외선 노출을 들 수 있다.The adverse effects on the skin can be divided into internal factors and external factors. Among the internal factors, free radicals generated by stress are mentioned, and the external factors include excessive UV exposure due to environmental pollution.
비타민 C는 피부, 혈액 및 기타 조직에서 강력한 생체 항산화제로 작용하는데, 두 개의 전자를 받아 디하이드로-L-아스코르브산 (Dehydro-L-ascorbic acid) 형태로 쉽게 산화되는 당유사 구조 (Sugar-like structure)를 갖고 있어서, 생체내에서 반응성이 높은 자유 라디칼 및 과산화물에 의해 단백질 등의 생체성분이 산화되거나 변성되는 것을 방지한다.Vitamin C acts as a powerful biological antioxidant in the skin, blood and other tissues, and has a sugar-like structure that accepts two electrons and is easily oxidized to the form of dehydro-L-ascorbic acid (Dehydro-L-ascorbic acid). ) to prevent oxidation or denaturation of biocomponents such as proteins by highly reactive free radicals and peroxides in the living body.
아울러, 비타민 C는 색소침착 억제 효과를 갖고 있는데, 이는 색소침착과 깊은 관련이 있는 멜라닌의 생성을 억제함으로써 달성된다. 비타민 C는 멜라닌 형성에 중요한 티로시나제의 활성을 억제하고, 산화 과정에 의해 형성된 산화형 멜라닌을 다시 환원시켜 환원형 멜라닌으로 변화시킴으로써 멜라닌에 의한 색소침착 증세를 개선시키는 효과를 갖고 있다.In addition, vitamin C has a pigmentation inhibitory effect, which is achieved by inhibiting the production of melanin, which is closely related to pigmentation. Vitamin C inhibits the activity of tyrosinase, which is important for the formation of melanin, and reduces the oxidized melanin formed by the oxidation process and changes it into reduced melanin, thereby improving the pigmentation symptoms caused by melanin.
비타민 C를 함유하는 화장료 조성물은 상기와 같은 유용한 효과를 가지고 있지만, 공기, 습기, 빛, 열, 금속이온, 산소, 염기 등에 의해 쉽게 산화되어 2,3-다이케토-L-굴론산 (2,3-diketo-L-gulonic acid), 옥살산 (oxalic acid), L-트레온산 (L-threonic acid), L-자일론산 (L-xylonic acid), L-라이존산 (L-Lyxonic acid) 등으로 산화된다. 이때 역가가 떨어지고 변색 변취가 일어나는 등 제형 내 안정성 및 안전성에 큰 문제점을 가지고 있다. 또한 다량의 순수 비타민 C는 사용감이 좋지 못하고 자극이 있다는 것은 통상적이며, 석출현상도 일어난다.Although the cosmetic composition containing vitamin C has the above useful effects, it is easily oxidized by air, moisture, light, heat, metal ions, oxygen, base, etc. to 2,3-diketo-L-gulonic acid (2 ,3-diketo-L-gulonic acid), oxalic acid, L-threonic acid, L-xylonic acid, L-Lyxonic acid, etc. is oxidized to At this time, there is a big problem in stability and safety in the formulation, such as a drop in potency and discoloration and odor. In addition, it is common that a large amount of pure vitamin C has a poor feeling of use and irritation, and precipitation occurs.
이러한 단점에도 불구하고 비타민 C가 가지고고 있는 생리활성이 높아 화장료, 제약 등에 꾸준히 이용되고 있는 실정이다. 또한 다양한 비타민 C 유도체를 합성하여 안정화하려는 노력으로 많은 연구가 진행되고 있다.Despite these shortcomings, the high physiological activity of vitamin C has been consistently used in cosmetics and pharmaceuticals. In addition, many studies are being conducted in an effort to synthesize and stabilize various vitamin C derivatives.
본 발명의 목적은 비타민 C를 포함하는 화장료 조성물 및 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition and a pharmaceutical composition comprising vitamin C.
본 발명의 목적은 비타민 C의 안정성이 높고, 피부 자극이 적으며, 피부 미백 효과가 우수한 조성물을 제공하는 것이다.An object of the present invention is to provide a composition having high stability of vitamin C, less skin irritation, and excellent skin whitening effect.
본 발명의 다른 목적은 비타민 C 함유 조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for preparing a vitamin C-containing composition.
상기 목적을 달성하기 위하여, 본 발명자들이 기존의 비타민 C 함유 조성물의 단점을 개선할 수 있도록 다양한 연구를 계속하던 중, 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상의 안정화제를 포함할 경우 우수한 비타민 C 함유 조성물이 제공될 수 있음을 확인하고 본 발명을 완성하였다.In order to achieve the above object, while the present inventors continued various studies to improve the disadvantages of the existing vitamin C-containing composition, one or more stabilizers selected from the group consisting of lemon myrtle extract, fullerene and oils and fats were included. When it is confirmed that an excellent vitamin C-containing composition can be provided, the present invention has been completed.
본 발명은,The present invention is
(i) 비타민 C; 및(i) vitamin C; and
(ii) 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상의 안정화제(ii) at least one stabilizer selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats
를 포함하는 화장료 조성물을 제공한다.It provides a cosmetic composition comprising a.
본 발명의 화장료 조성물은 비타민 C의 효과에 의하여 피부 미백용으로 사용될 수 있다.The cosmetic composition of the present invention can be used for skin whitening by the effect of vitamin C.
본 발명의 일 실시양태에서, 화장료 조성물은 안정화제로 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 2종 이상의 안정화제를 포함할 수 있다. 본 발명의 구체적인 일 실시예에서, 화장료 조성물은 안정화제로 레몬머틀 추출물 및 풀러렌을 포함할 수 있다. 본 발명의 구체적인 다른 실시예에서, 화장료 조성물은 안정화제로 레몬머틀 추출물, 풀러렌 및 유지류를 포함할 수 있다.In one embodiment of the present invention, the cosmetic composition may include two or more stabilizers selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats as stabilizers. In a specific embodiment of the present invention, the cosmetic composition may include lemon myrtle extract and fullerene as stabilizers. In another specific embodiment of the present invention, the cosmetic composition may include lemon myrtle extract, fullerene and oils and fats as stabilizers.
본 발명의 일 실시양태에서, 화장료 조성물에 포함되는 비타민 C는 순수한 아스코르브산일 수 있다.In one embodiment of the present invention, vitamin C included in the cosmetic composition may be pure ascorbic acid.
본 발명의 일 실시양태에서, 화장료 조성물에 포함되는 유지류는 탄화수소, 실리콘, 유용성 비타민 유도체 및 에스터 오일로 이루어진 군에서 선택되는 1종 이상일 수 있다. 본 발명의 구체적인 일 실시예에서, 상기 탄화수소는 C 18-21 알칸일 수 있다.In one embodiment of the present invention, the oils and fats included in the cosmetic composition may be at least one selected from the group consisting of hydrocarbons, silicones, oil-soluble vitamin derivatives, and ester oils. In a specific embodiment of the present invention, the hydrocarbon may be a C 18-21 alkane.
본 발명의 일 실시양태에서, 비타민 C의 함량은 30 w/v% 이하, 바람직하게는 1 내지 20 w/v%일 수 있다.In one embodiment of the present invention, the content of vitamin C may be 30 w/v% or less, preferably 1 to 20 w/v%.
본 발명의 일 실시양태에서, 유지류의 함량은 1 내지 20 w/v%일 수 있다.In one embodiment of the present invention, the content of oils and fats may be 1 to 20 w/v%.
본 발명의 일 실시양태에서, 화장료 조성물은 피부 미백용 기능성 화장품일 수 있다.In one embodiment of the present invention, the cosmetic composition may be a functional cosmetic for skin whitening.
본 발명은, The present invention is
(i) 비타민 C; 및(i) vitamin C; and
(ii) 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상의 안정화제(ii) at least one stabilizer selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats
를 포함하는 미백용 약학적 조성물을 제공한다.It provides a pharmaceutical composition for whitening comprising a.
본 발명은, 수성 용매에 비타민 C, 레몬머틀 추출물 및 풀러렌을 혼합하여 혼합물을 제조하는 단계를 포함하는, 비타민 C를 포함하는 조성물의 제조방법을 제공한다.The present invention provides a method for preparing a composition comprising vitamin C, comprising the step of preparing a mixture by mixing vitamin C, lemon myrtle extract and fullerene in an aqueous solvent.
본 발명의 조성물은 비타민 C의 안정성이 높다. 따라서 본 발명의 조성물은 저장안정성이 뛰어나 장기간 동안 안정적으로 비타민 C의 효과를 유지할 수 있다. 또한, 본 발명의 조성물은 다량의 비타민 C를 함유하는 경우에도 안정성을 확보할 수 있다.The composition of the present invention has high vitamin C stability. Therefore, the composition of the present invention has excellent storage stability and can stably maintain the effect of vitamin C for a long period of time. In addition, the composition of the present invention can ensure stability even when it contains a large amount of vitamin C.
본 발명의 조성물은 피부에 적용하였을 때 자극이 적다. 따라서 본 발명의 조성물은 피부가 민감하거나, 약한 대상도 불편감 없이 사용할 수 있다.The composition of the present invention is less irritating when applied to the skin. Therefore, the composition of the present invention can be used without discomfort even for sensitive or weak skin.
본 발명의 조성물은 피부 미백, 주름 개선, 탄력 향상 및 항산화 작용을 나타낸다. 따라서 화장료 및 약학적 조성물로 유용하게 사용될 수 있다.The composition of the present invention exhibits skin whitening, wrinkle improvement, elasticity improvement and antioxidant action. Therefore, it can be usefully used as a cosmetic and pharmaceutical composition.
화장료 조성물cosmetic composition
본 발명의 화장료 조성물은, (i) 비타민 C; 및 (ii) 1종 이상의 안정화제를 포함한다. 상기 안정화제는 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상일 수 있다. The cosmetic composition of the present invention comprises: (i) vitamin C; and (ii) at least one stabilizing agent. The stabilizer may be at least one selected from the group consisting of lemon myrtle extract, fullerene, and oils and fats.
본 발명에서, “비타민 C”는 하기 화학식 I의 구조를 가지는 아스코르브산(Ascorbic acid) 또는 이의 유도체, 또는 이들의 염 또는 용매화물을 의미한다.In the present invention, "vitamin C" means ascorbic acid having the structure of the following formula (I) or a derivative thereof, or a salt or solvate thereof.
[화학식 I] [Formula I]
Figure PCTKR2020014311-appb-img-000001
Figure PCTKR2020014311-appb-img-000001
본 발명의 바람직한 실시예에서, 비타민 C는 순수한 아스코르브산일 수 있다. 본 발명에서 순수한 아스코르브산은 전체 비타민 C에 대하여, 아스코르브산의 유도체가 아닌 상기 [화학식 I] 구조의 화합물의 함량이 90%이상, 바람직하게는 95% 이상, 보다 바람직하게는 99% 이상인 것을 의미한다.In a preferred embodiment of the present invention, vitamin C may be pure ascorbic acid. In the present invention, pure ascorbic acid means that the content of the compound of the structure [Formula I], which is not a derivative of ascorbic acid, is 90% or more, preferably 95% or more, more preferably 99% or more with respect to the total vitamin C. .
비타민 C는 멜라닌 생성을 막아 피부 미백 작용을 하고, 피부를 구성하는 콜라겐 합성을 도와 주름 개선과 탄력 향상에도 효과가 있다. 또한, 자외선, 미세먼지 등의 공해, 및 스트레스로 인해 발생하는 활성산소를 억제하는 항산화 효과도 나타낸다. 다만, 비타민 C는 열, 빛, 물, 산소 등에 쉽게 파괴되는 민감한 물질이므로, 그 안정성을 유지하는 것이 중요하다.Vitamin C prevents the production of melanin and whitens the skin, and helps to synthesize collagen that makes up the skin, thereby improving wrinkles and improving elasticity. In addition, it also exhibits an antioxidant effect that suppresses free radicals generated due to pollution such as ultraviolet rays and fine dust, and stress. However, since vitamin C is a sensitive substance that is easily destroyed by heat, light, water, and oxygen, it is important to maintain its stability.
본 발명의 화장료 조성물은 비타민 C의 안정성이 매우 우수하므로, 효과적으로 피부 미백, 주름 개선, 탄력 향상, 항산화 효과를 나타낼 수 있다.Since the cosmetic composition of the present invention has very excellent vitamin C stability, it can effectively exhibit skin whitening, wrinkle improvement, elasticity improvement, and antioxidant effects.
본 발명에서, “레몬머틀(Lemon myrtle)”은 도금양과(Myrtaceae)의 식물로 학명은 Backhousia citriodora이며, 레몬센티드 머틀(Lemon scented myrtle), 레몬센티드 아이언우드(Lemon scented ironwood), 스윗버베나 트리(Sweet verbena tree), 스윗버베나 머틀(Sweet verbena myrtle), 레몬 센티드 버베나(Lemon scented verbena), 레몬 센티드 백하우시아(Lemon scented backhousia) 등으로도 불린다. 레몬머틀은 호주의 퀸즐랜드 중앙과 남동지역 아열대 우림지방에서 주로 자생한다.In the present invention, "lemon myrtle" is a plant of the family Myrtaceae, and the scientific name is Backhousia citriodora , lemon scented myrtle, lemon scented ironwood, sweet verbena. It is also called sweet verbena tree, sweet verbena myrtle, lemon scented verbena, lemon scented backhousia, etc. Lemon myrtle is native to the subtropical rain forests of central and southeastern Queensland, Australia.
본 발명에서, “추출물”은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 천연물의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 것이며, 또한 천연물의 성분을 뽑아내어 얻어진 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함하는 광범위한 개념이다. 상기 “가공 또는 처리”는 예를 들어, 추출물을 추가적으로 발효 또는 효소 처리하는 것일 수 있다.In the present invention, the term "extract" includes all substances obtained by extracting the components of a natural product, regardless of the extraction method, extraction solvent, extracted component or the form of the extract, and extracting the material obtained by extracting the component of the natural product It is a broad concept that includes all substances that can be obtained by further processing or processing in other ways. The "processing or treatment" may be, for example, additional fermentation or enzymatic treatment of the extract.
따라서 본원에서 추출물은 분획물, 추출액 또는 분획물의 조정제물이나 정제물, 또는 이들의 희석액, 농축물, 건조물, 발효물, 또는 이들의 혼합물 등, 레몬머틀로부터 형성가능한 모든 제형의 추출물을 포함하는 광범위한 개념이다. Accordingly, as used herein, an extract is a fraction, an extract or a crude product or purified product of a fraction, or a dilution, concentrate, dried product, fermented product, or mixture thereof, and the like, including extracts of all formulations formable from lemon myrtle. to be.
본 발명에서, “레몬머틀 추출물”은 레몬머틀의 잎, 꽃, 뿌리, 줄기, 열매 및 이들의 조합인 초본 전체의 추출물일 수 있으며, 초본의 지상부 또는 뿌리부의 일부 또는 전부의 추출물일 수 있고, 바람직하게는 레몬머틀 전초의 추출물일 수 있고, 보다 바람직하게는 레몬머틀 잎의 추출물 일 수 있다.In the present invention, the “lemon myrtle extract” may be an extract of the whole herb, which is the leaf, flower, root, stem, fruit, or a combination thereof, of lemon myrtle, and may be an extract of a part or all of the above-ground part or root part of the herb; Preferably, it may be an extract of lemon myrtle whole plant, and more preferably, it may be an extract of lemon myrtle leaves.
본 발명에서 레몬머틀 추출물은 이 분야에 공지된 일반적 제조방법을 사용하여 제조될 수 있으며, 특별히 제한되지 않는다. 예를 들어, 초음파 추출법, 초임계 추출법, 감압 추출법 환류 추출법, 열수 추출법, 저온 열수 추출법, 고온 가압 추출법, 저온 고압 추출법, 초고압 추출법, 효소 추출법, 용매 추출법, 냉침 추출법, 수증기 증류법, 저온 고압 증류법, 용출법, 압착법, 가열 추출법, 또는 추출 용매를 사용하여 공지의 방법에 의해 제조하는 방법일 수 있으나, 이에 한정되는 것은 아니다. 본 발명의 바람직한 실험예에서, 레몬머틀 추출물은 저온 고압 증류법으로 수득된 것일 수 있다.In the present invention, the lemon myrtle extract may be prepared using a general preparation method known in the art, and is not particularly limited. For example, ultrasonic extraction method, supercritical extraction method, vacuum extraction method reflux extraction method, hot water extraction method, low temperature hot water extraction method, high temperature pressure extraction method, low temperature high pressure extraction method, ultra high pressure extraction method, enzyme extraction method, solvent extraction method, cold extraction method, steam distillation method, low temperature high pressure distillation method, It may be prepared by a known method using an elution method, a compression method, a heat extraction method, or an extraction solvent, but is not limited thereto. In a preferred experimental example of the present invention, the lemon myrtle extract may be obtained by low-temperature high-pressure distillation.
본 발명에서, 레몬머틀 추출물은 물, 유기용매 또는 이들의 혼합물을 추출 용매로 하여 추출액으로 제조될 수 있다. 상기 물은 예를 들어, 증류수, 정제수, 무균수를 들 수 있으나, 이에 한정되는 것은 아니다. 상기 유기용매는 예를 들어, 알코올, 글리세린, 부틸렌글리콜, 프로필렌글리콜, 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르 및 디클로로메탄를 들 수 있으나, 이에 한정되는 것은 아니다. In the present invention, the lemon myrtle extract may be prepared as an extract using water, an organic solvent, or a mixture thereof as an extraction solvent. The water may include, for example, distilled water, purified water, or sterile water, but is not limited thereto. The organic solvent may include, for example, alcohol, glycerin, butylene glycol, propylene glycol, methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane, but is not limited thereto.
본 발명에서, 레몬머틀 추출물은 바람직하게는 물, C 1-6 알코올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸 아세테이트, 메틸렌클로라이드, 헥산, 시클로헥산 및 이들의 혼합물로 이루어진 군에서 선택되는 용매를 추출 용매로 하여 추출된 것일 수 있다. 상기 C 1-6 알코올 의 농도는 10 % 내지 90 %일 수 있고, 바람직하게는 30 % 내지 90 % 일 수 있고, 더 바람직하게는 50 % 내지 90 % 일 수 있다. In the present invention, the lemon myrtle extract is preferably extracted with a solvent selected from the group consisting of water, C 1-6 alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, and mixtures thereof. It may be extracted with a solvent. The concentration of the C 1-6 alcohol may be 10% to 90%, preferably 30% to 90%, and more preferably 50% to 90%.
본 발명의 레몬머틀 추출물은 상업적으로 유통되는 제품을 구매하거나, 상기 기재된 공지의 추출 방법으로 제조될 수 있으며, 바람직하게는 저온의 증류수 중에서 추출될 수 있다. 본 발명의 바람직한 실시예에서 레몬머틀 추출물은 레몬머틀 증류수 일 수 있다.The lemon myrtle extract of the present invention may be purchased commercially, or may be prepared by the known extraction method described above, and preferably extracted in distilled water at low temperature. In a preferred embodiment of the present invention, the lemon myrtle extract may be lemon myrtle distilled water.
본 발명의 화장료 조성물에서, 레몬머틀 추출물은 비타민 C의 내부 산화 안정도를 증가시켜 비타민 C가 수분, 온도, 공기 등의 외부환경에 의해 분해 및 산화되는 것을 효과적으로 방지할 수 있다.In the cosmetic composition of the present invention, the lemon myrtle extract can effectively prevent the decomposition and oxidation of vitamin C by external environments such as moisture, temperature, and air by increasing the internal oxidation stability of vitamin C.
본 발명에서, “풀러렌(Fullerene)”은 하기 [화학식 II]의 구조의 60개의 탄소 원자로 이루어진 탄소의 동소체로, 축구공처럼 생겨 안정된 구조를 가지는 탄소결합구조이다.In the present invention, "Fullerene" is an allotrope of carbon consisting of 60 carbon atoms of the structure of the following [Formula II], and is a carbon-bonded structure having a stable structure that is formed like a soccer ball.
[화학식 II][Formula II]
Figure PCTKR2020014311-appb-img-000002
Figure PCTKR2020014311-appb-img-000002
풀러렌은 절연성, 유기용매가용성, 열적안정성, 열분해억제성, 항산화성을 가지고 있으며, 이러한 특성들을 활용하여, 자성체, 광학재료, 초전도재료, 의료, 이차전지, 윤활유 등 많은 분야에서 지속적으로 적용이 검토되고 있다.Fullerene has insulation, organic solvent solubility, thermal stability, thermal decomposition inhibition, and antioxidant properties, and by utilizing these properties, its application is continuously reviewed in many fields such as magnetic materials, optical materials, superconducting materials, medical care, secondary batteries, and lubricants. is becoming
본 발명의 화장료 조성물에서, 풀러렌은 비타민 C의 내부 산화 안정도를 증가시켜 비타민 C가 수분, 온도, 공기 등의 외부환경에 의해 분해 및 산화되는 것을 효과적으로 방지할 수 있다.In the cosmetic composition of the present invention, fullerene can effectively prevent decomposition and oxidation of vitamin C by external environments such as moisture, temperature, and air by increasing the internal oxidation stability of vitamin C.
본 발명에서, 유지류는 용액이 유상과 수상으로 나뉠 때 유상 부분에 존재할 수 있는 물질들을 의미한다. 본 발명에서 유지류는 예를 들어, 탄화수소(Hydrocarbon), 실리콘(Silicon), 유용성 비타민 유도체 또는 에스터 오일(Ester oil)을 들 수 있다.In the present invention, oils and fats refer to substances that may exist in the oil phase when the solution is divided into an oil phase and an aqueous phase. In the present invention, oils and fats may include, for example, hydrocarbons, silicones, oil-soluble vitamin derivatives, or ester oils.
본 발명의 화장료 조성물은 탄화수소, 실리콘, 유용성 비타민 유도체 및 에스터 오일로 이루어진 군에서 선택되는 1종 이상의 유지류를 포함할 수 있다.The cosmetic composition of the present invention may include one or more oils and fats selected from the group consisting of hydrocarbons, silicones, oil-soluble vitamin derivatives, and ester oils.
본 발명의 화장료 조성물에서, 유지류는 유중수 분산 제형의 내상에 비타민 C를 포집하여 안정화시킴으로써 수분, 온도, 공기 등의 외부환경에 의해 분해 및 산화되는 것을 효과적으로 방지하고, 비타민 C의 끈적임과 밀림 현상을 개선하여 표면의 산소를 차단하는 메커니즘을 이용해 안정성을 확보할 수 있다.In the cosmetic composition of the present invention, oils and fats effectively prevent decomposition and oxidation by external environments such as moisture, temperature, and air by capturing and stabilizing vitamin C in the inner layer of the water-in-oil dispersion formulation, and the stickiness and slipping phenomenon of vitamin C It is possible to secure stability by using a mechanism to block oxygen on the surface.
본 발명의 화장료 조성물에서, 유지류는 비타민 C와 외부 공기의 접촉을 막아주는 보호제 역할을 하여 외부의 산화 요인으로부터 비타민 C, 바람직하게는 비타민 C가 용해되어 있는 수용액의 산화를 방지해 줄 수 있다.In the cosmetic composition of the present invention, oils and fats act as a protective agent that prevents contact between vitamin C and external air, thereby preventing oxidation of an aqueous solution in which vitamin C, preferably vitamin C, is dissolved from external oxidizing factors.
상기 탄화수소는 직쇄 또는 분지쇄의 알칸, 알켄 또는 알카인일 수 있으며, 바람직하게는 C 12-25 알칸, 보다 바람직하게는 C 18-21 알칸 일 수 있다.The hydrocarbon may be a straight-chain or branched alkane, alkene, or alkyne, preferably a C 12-25 alkane, more preferably a C 18-21 alkane.
상기 실리콘은 유기규소 화합물의 중합체로, 규소를 주성분으로 하는 고분자를 의미한다. The silicon is a polymer of an organosilicon compound, and refers to a polymer containing silicon as a main component.
상기 유용성 비타민 유도체는 지방에 잘 녹는 비타민으로서 비타민 A, D, E, K 또는 이들이 유도체를 들 수 있으며, 예를 들어, 토코페롤, 토코페릴아세테이트 토코트리에놀을 들 수 있다.The oil-soluble vitamin derivative is a vitamin soluble in fat, and includes vitamins A, D, E, and K or derivatives thereof, for example, tocopherol and tocopheryl acetate tocotrienol.
상기 에스터 오일은 RC(=O)OR'(R 및 R'는 탄소를 포함하는 작용기)구조를 가지는 오일을 의미하며, 예를 들어, 아나토씨오일, 에몰리언트를 들 수 있다.The ester oil means an oil having a structure of RC(=O)OR' (R and R' are functional groups including carbon), for example, annatto oil and emollient.
본 발명의 화장료 조성물에서, 안정화제는 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 2종 이상일 수 있다. 예를 들어, 본 발명은 레몬머틀 추출물 및 풀러렌을 포함하는 화장료 조성물, 레몬머틀 추출물 및 유지류를 포함하는 화장료 조성물, 풀러렌 및 유지류를 포함하는 화장료 조성물, 또는 레몬머틀 추출물, 풀러렌 및 유지류를 포함하는 화장료 조성물 일 수 있다.In the cosmetic composition of the present invention, the stabilizer may be two or more selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats. For example, the present invention provides a cosmetic composition comprising a lemon myrtle extract and fullerene, a cosmetic composition comprising a lemon myrtle extract and oils and fats, a cosmetic composition comprising a fullerene and fats and oils, or a cosmetic comprising a lemon myrtle extract, fullerene and oils and fats. It may be a composition.
본 발명의 구체적인 실시예에서, 화장료 조성물은 안정화제로 풀러렌 만을 포함할 수 있으며, 추가로 레몬머틀 추출물을 더 포함할 수도 있다. 또한, 본 발명의 바람직한 실시예에 의하면, 화장료 조성물은 안정화제로 레몬머틀 추출물, 풀러렌 및 유지류를 포함한다.In a specific embodiment of the present invention, the cosmetic composition may include only fullerene as a stabilizer, and may further include a lemon myrtle extract. In addition, according to a preferred embodiment of the present invention, the cosmetic composition includes lemon myrtle extract, fullerene and oils and fats as stabilizers.
본 발명의 화장료 조성물은, 비타민 C 이외에 화장료로 기능성이 있는 추가적인 유효성분을 더 포함할 수 있다. 예를 들어, 본 발명의 화장료 조성물은 미백, 주름 개선, 보습, 각질 제거, 탄력 개선, 항산화 또는 유분 조절 등에 효과가 있는 추가적인 유효성분을 더 포함할 수 있다.The cosmetic composition of the present invention may further include an additional active ingredient functional as a cosmetic in addition to vitamin C. For example, the cosmetic composition of the present invention may further include additional active ingredients effective for whitening, wrinkle improvement, moisturizing, exfoliation, elasticity improvement, antioxidant or oil control, and the like.
본 발명의 구체적인 실시예에서, 본 발명의 화장료 조성물은 비타민 A 또는 비타민 D를 추가로 더 포함할 수 있다. 상기 비타민 A 및 비타민 D는 미백을 비롯한 다양한 피부 개선 효능을 가진다. 또한, 비타민 A 및 비타민 D는 지용성 비타민이므로, 본 발명의 화장료 조성물에서 안정화제로도 기능을 함께 나타낼 수 있다.본 발명의 화장료 조성물에서, 비타민 C의 함량은 50 w/v% 이하, 바람직하게는 30 w/v% 이하, 보다 바람직하게는 20 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 비타민 C의 함량은 0.1 w/v% 이상, 바람직하게는 1 w/v% 이상, 보다 바람직하게는 10 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서, 비타민 C의 함량은 10 내지 20 w/v%일 수 있다.In a specific embodiment of the present invention, the cosmetic composition of the present invention may further include vitamin A or vitamin D. The vitamin A and vitamin D have various skin improvement effects including whitening. In addition, since vitamin A and vitamin D are fat-soluble vitamins, they may also function as stabilizers in the cosmetic composition of the present invention. In the cosmetic composition of the present invention, the content of vitamin C is 50 w/v% or less, preferably 30 w/v% or less, more preferably 20 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of vitamin C may be 0.1 w/v% or more, preferably 1 w/v% or more, more preferably 10 w/v% or more. In a specific embodiment of the present invention, the content of vitamin C may be 10 to 20 w / v%.
본 발명의 화장료 조성물에서, 레몬머틀 추출물의 함량은 90 w/v% 이하, 바람직하게는 80 w/v% 이하, 보다 바람직하게는 70 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 레몬머틀 추출물의 함량은 0.1 w/v% 이상, 바람직하게는 5 w/v% 이상, 보다 바람직하게는 10 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서, 레몬머틀 추출물의 함량은 10 내지 70 w/v%일 수 있다.In the cosmetic composition of the present invention, the content of the lemon myrtle extract may be 90 w/v% or less, preferably 80 w/v% or less, and more preferably 70 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of the lemon myrtle extract may be 0.1 w/v% or more, preferably 5 w/v% or more, and more preferably 10 w/v% or more. In a specific embodiment of the present invention, the content of the lemon myrtle extract may be 10 to 70 w / v%.
본 발명의 화장료 조성물에서, 풀러렌의 함량은 5 ppm 이하, 바람직하게는 3 ppm 이하, 보다 바람직하게는 2 ppm 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 풀러렌의 함량은 0.01 ppm 이상, 바람직하게는 0.1 ppm 이상, 보다 바람직하게는 1.0 ppm 이상일 수 있다. 본 발명의 구체적인 실시예에서 풀러렌의 함량은 1.0 내지 2 ppm일 수 있다.In the cosmetic composition of the present invention, the content of fullerene may be 5 ppm or less, preferably 3 ppm or less, more preferably 2 ppm or less. In addition, in the cosmetic composition of the present invention, the content of fullerene may be 0.01 ppm or more, preferably 0.1 ppm or more, more preferably 1.0 ppm or more. In a specific embodiment of the present invention, the content of fullerene may be 1.0 to 2 ppm.
본 발명의 화장료 조성물에서, 풀러렌의 함량은 0.0005 w/v% 이하, 바람직하게는 0.0003 w/v% 이하, 보다 바람직하게는 0.0002 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 풀러렌의 함량은 0.000001 w/v% 이상, 바람직하게는 0.00001 w/v% 이상, 보다 바람직하게는 0.0001 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서 풀러렌의 함량은 0.0001 w/v% 내지 0.0002 w/v%일 수 있다.In the cosmetic composition of the present invention, the content of fullerene may be 0.0005 w/v% or less, preferably 0.0003 w/v% or less, and more preferably 0.0002 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of fullerene may be 0.000001 w/v% or more, preferably 0.00001 w/v% or more, and more preferably 0.0001 w/v% or more. In a specific embodiment of the present invention, the content of fullerene may be 0.0001 w/v% to 0.0002 w/v%.
본 발명의 화장료 조성물에서, 유지류의 함량은 50 w/v% 이하, 바람직하게는 30 w/v% 이하, 보다 바람직하게는 20 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 유지류의 함량은 0.1 w/v% 이상, 보다 바람직하게는 1 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서 유지류의 함량은 1 내지 20 w/v%일 수 있다.In the cosmetic composition of the present invention, the content of oils and fats may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of oils and fats may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of oils and fats may be 1 to 20 w/v%.
본 발명의 화장료 조성물에서, C 18-21 알칸의 함량은 50 w/v% 이하, 바람직하게는 30 w/v% 이하, 보다 바람직하게는 20 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, C 18-21 알칸의 함량은 0.1 w/v% 이상, 보다 바람직하게는 1 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서 C 18-21 알칸의 함량은 1 내지 20 w/v%일 수 있다.In the cosmetic composition of the present invention, the content of C 18-21 alkane may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of C 18-21 alkane may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of C 18-21 alkane may be 1 to 20 w/v%.
본 발명의 화장료 조성물에서, 실리콘의 함량은 50 w/v% 이하, 바람직하게는 30 w/v% 이하, 보다 바람직하게는 20 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 실리콘의 함량은 0.1 w/v% 이상, 보다 바람직하게는 1 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서 실리콘의 함량은 1 내지 20 w/v%일 수 있다.본 발명의 화장료 조성물에서, 유용성 비타민 유도체의 함량은 50 w/v% 이하, 바람직하게는 30 w/v% 이하, 보다 바람직하게는 20 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 유용성 비타민 유도체의 함량은 0.1 w/v% 이상, 보다 바람직하게는 1 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서 유용성 비타민 유도체의 함량은 1 내지 20 w/v%일 수 있다.In the cosmetic composition of the present invention, the content of silicone may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of silicone may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of silicone may be 1 to 20 w/v%. In the cosmetic composition of the present invention, the content of the oil-soluble vitamin derivative is 50 w/v% or less, preferably 30 w/v% or less, more preferably 20 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of the oil-soluble vitamin derivative may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of the oil-soluble vitamin derivative may be 1 to 20 w/v%.
본 발명의 화장료 조성물에서, 에스터 오일의 함량은 50 w/v% 이하, 바람직하게는 30 w/v% 이하, 보다 바람직하게는 20 w/v% 이하일 수 있다. 또한, 본 발명의 화장료 조성물에서, 에스터 오일의 함량은 0.1 w/v% 이상, 보다 바람직하게는 1 w/v% 이상일 수 있다. 본 발명의 구체적인 실시예에서 에스터 오일의 함량은 1 내지 20 w/v%일 수 있다.In the cosmetic composition of the present invention, the content of the ester oil may be 50 w/v% or less, preferably 30 w/v% or less, and more preferably 20 w/v% or less. In addition, in the cosmetic composition of the present invention, the content of the ester oil may be 0.1 w/v% or more, more preferably 1 w/v% or more. In a specific embodiment of the present invention, the content of ester oil may be 1 to 20 w/v%.
본 발명의 화장료 조성물은 미백에 특히 효과과 우수하여, 피부 미백용 기능성 화장품으로 사용될 수 있다. The cosmetic composition of the present invention is particularly effective and excellent in whitening, and can be used as a functional cosmetic for skin whitening.
본 발명의 화장료 조성물은 또한, 주름 개선에 효과가 우수하여, 주름 개선용 기능성 화장품으로 사용될 수 있다.The cosmetic composition of the present invention also has excellent anti-wrinkle effect, and can be used as a functional cosmetic for wrinkle improvement.
본 발명의 화장료 조성물은 우수한 안정성을 나타내어 비타민 C의 역가가 감소하지 않고 장시간 보존될 수 있다. 본 발명의 구체적인 실험예에 의하면, 본 발명의 화장료 조성물은 40℃ 이하에서 우수한 안정성을 나타낸다. 구체적으로, 본 발명의 화장료 조성물은 5℃에서 우수한 안정성을 나타내는 것이 확인되었다. 또한 본 발명의 화장료 조성물은 25℃에서 우수한 안정성을 나타내는 것이 확인되었다. 나아가 본 발명의 화장료 조성물은 40℃에서 우수한 안정성을 나타내는 것이 확인되었다. 따라서, 본 발명의 화장료 조성물은 5℃ 내지 40℃, 5 내지 30℃, 또는 5 내지 25℃에서 우수한 안정성을 나타낸다.The cosmetic composition of the present invention exhibits excellent stability and can be stored for a long time without decreasing the titer of vitamin C. According to a specific experimental example of the present invention, the cosmetic composition of the present invention exhibits excellent stability at 40° C. or less. Specifically, it was confirmed that the cosmetic composition of the present invention exhibits excellent stability at 5°C. In addition, it was confirmed that the cosmetic composition of the present invention exhibits excellent stability at 25°C. Furthermore, it was confirmed that the cosmetic composition of the present invention exhibits excellent stability at 40°C. Accordingly, the cosmetic composition of the present invention exhibits excellent stability at 5°C to 40°C, 5 to 30°C, or 5 to 25°C.
또한, 본 발명의 화장료 조성물은 안정화제로 레몬머틀 추출물, 풀러렌 및 유지로로 이루어진 군에서 선택되는 1종 이상을 포함하더라도, 피부자극이 발생하지 않고, 우수한 피부 미백 효과가 유지된다.In addition, even if the cosmetic composition of the present invention contains at least one selected from the group consisting of lemon myrtle extract, fullerene, and oil and fat as a stabilizer, skin irritation does not occur and excellent skin whitening effect is maintained.
본 발명의 화장료 조성물은 이 기술분야에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화 될 수 있으나, 이에 한정되는 것은 아니 다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 팩, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing It may be formulated as cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, a pack, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a spray, or a powder.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, bentonite, silica, talc, or zinc oxide is used as a carrier component. can be
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더 등이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder, etc. may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluoro propellants such as hydrocarbons, propane/butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예를 들어, 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 부틸렌글리콜, 1,3-부틸글리콜 오일, 폴리옥시에틸렌 경화피마자유, 글리세롤, 글리세린, 지방족 에스테르, 페녹시에탄올, 트리에탄올아민, 폴리에틸렌 글리콜, 밀납, 폴리솔베이트 60, 솔비탄세스 퀴오레이드, 파라핀, 소르비탄 스테아레이트, 친유형 모노스테아린산 글리세린, 스테아린산, 글리세릴스테아레 이트/피이지-400 스테아레이트, 카르복시폴리머, 시토스테롤, 폴리글리세릴 2-올레이트, 세라마이드, 콜레스테 롤, 스테아레스-4, 디세틸포스페이트, 마카다미아 오일, 카르복시비닐폴리머, 산탄검 또는 소르비탄의 지방산 에스테르 등이 있다. When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzo Eight, propylene glycol, butylene glycol, 1,3-butyl glycol oil, polyoxyethylene hydrogenated castor oil, glycerol, glycerin, aliphatic ester, phenoxyethanol, triethanolamine, polyethylene glycol, beeswax, polysorbate 60, sorbitan Sesquioride, Paraffin, Sorbitan Stearate, Lipophilic Monostearate Glycerin, Stearic Acid, Glyceryl Stearate/PEG-400 Stearate, Carboxypolymer, Sitosterol, Polyglyceryl 2-oleate, Ceramide, Cholesterol , steareth-4, dicetyl phosphate, macadamia oil, carboxyvinyl polymer, xanthan gum or fatty acid ester of sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올, 부틸렌글리콜 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미결정 셀룰로오스, 하이드록시에틸셀룰로오즈, 소듐 히알루로네이트, 페녹시에탄올, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol, butylene glycol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester Suspending agents such as, microcrystalline cellulose, hydroxyethyl cellulose, sodium hyaluronate, phenoxyethanol, aluminum metahydroxide, bentonite, agar or tracanth may be used.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate as carrier components , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
본 발명의 구체적인 실시예에서, 본 발명의 화장료 조성물은 화장학적으로 허용가능한 첨가제를 포함할 수 있으며, 예를 들어, 가용화제, 점증제 및 계면활성제에서 선택되는 1종 이상의 첨가제를 포함할 수 있다. 본 발명의 바람직한 실시예에 의하면, 본 발명의 화장료 조성물은 가용화제 및 점증제를 포함할 수 있다.In a specific embodiment of the present invention, the cosmetic composition of the present invention may include a cosmetically acceptable additive, for example, may include one or more additives selected from solubilizers, thickeners and surfactants. . According to a preferred embodiment of the present invention, the cosmetic composition of the present invention may include a solubilizer and a thickener.
상기 가용화제는 예를 들어, 폴리글리세릴-10라우레이트, 폴리글리세릴-4라우레이트, 옥틸도데세스-16일, PEG-40 수소화 피자아 오일, PEG-1-PEG-9 라우릴 글리골 에테르, C 12-13 파레스 9, 헵틸 글루코스 및 솔비탄 올레이트를 들 수 있으며, 이에 한정되는 것은 아니다. 본 발명의 구체적인 실시예에서, 가용화제는 폴리글리세릴-10라우레이트, 폴리글리세릴-4라우레이트 및 옥틸도데세스-16일에서 선택되는 1종 이상일 수 있다. 본 발명의 바람직한 실시예에서, 본 발명의 화장료 조성물은 가용화제로 폴리글리세릴-10라우레이트, 폴리글리세릴-4라우레이트 및 옥틸도데세스-16을 포함할 수 있다.The solubilizer is, for example, polyglyceryl-10 laurate, polyglyceryl-4 laurate, octyldodeses-16yl, PEG-40 hydrogenated pizza oil, PEG-1-PEG-9 lauryl glygol ethers, C 12-13 pareth 9, heptyl glucose and sorbitan oleate. In a specific embodiment of the present invention, the solubilizing agent may be at least one selected from polyglyceryl-10 laurate, polyglyceryl-4 laurate, and octyldodeses-16yl. In a preferred embodiment of the present invention, the cosmetic composition of the present invention may include polyglyceryl-10 laurate, polyglyceryl-4 laurate and octyldodeses-16 as solubilizers.
상기 점증제는 예를 들어, 친수성 실리카, 다당류, 알지네이트, 잔탄검, 카보머, 카르복시메틸 셀룰로오스, 하이드록시에틸 셀룰로오스, 하이드록시에틸프로필셀룰로오스, 하이드록시프로필셀룰로오스, 폴리에틸렌 글리콜 에스테르, 폴리아크릴레이트, 폴리아크릴아마이드, 폴리비닐알코올, 폴리비닐피롤리돈, 사이클로펜타실록산, 다이스테아다이모 헥토라이드, 프로필렌 카보네이트, 카올린, 칼라민, 스멕타이드 점토 등을 들 수 있으며, 이에 한정되는 것은 아니다. 본 발명의 구체적인 실시예에서, 점증제는 하이드록시에틸셀룰로오스일 수 있다.The thickener is, for example, hydrophilic silica, polysaccharide, alginate, xanthan gum, carbomer, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxyethylpropylcellulose, hydroxypropylcellulose, polyethylene glycol ester, polyacrylate, poly acrylamide, polyvinyl alcohol, polyvinylpyrrolidone, cyclopentasiloxane, disteadimo hectoride, propylene carbonate, kaolin, calamine, smectide clay, and the like, but is not limited thereto. In a specific embodiment of the present invention, the thickening agent may be hydroxyethylcellulose.
약학적 조성물pharmaceutical composition
본 발명의 약학적 조성물은, (i) 비타민 C; 및 (ii) 1종 이상의 안정화제를 포함하는 미백용 약학적 조성물이다. 상기 안정화제는 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상일 수 있다. The pharmaceutical composition of the present invention comprises: (i) vitamin C; and (ii) at least one stabilizer. The stabilizer may be at least one selected from the group consisting of lemon myrtle extract, fullerene, and oils and fats.
본 발명의 약학적 조성물에서, 비타민 C, 레몬머틀 추출물, 풀러렌, 유지류에 관한 서술은 앞서 화장료 조성물에서 서술한 바와 같다.In the pharmaceutical composition of the present invention, the description of vitamin C, lemon myrtle extract, fullerene, and oils and fats is the same as described above in the cosmetic composition.
본 발명의 약학적 조성물은 본 발명의 효과를 해치지 않는 범위에서 약학적으로 허용되는 담체를 추가로 포함할 수 있다. 본 발명에서 사용될 수 있는 약학적으로 허용되는 담체의 종류는 특별히 제한되지 아니하며, 이 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체는 예를 들어, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 말토 덱스트린, 글리세롤, 에탄올 등을 들 수 있으나, 이에 한정되는 것은 아니다. 상기 담체는 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier in a range that does not impair the effects of the present invention. The type of pharmaceutically acceptable carrier that can be used in the present invention is not particularly limited, and any carrier commonly used in the art may be used. The carrier may include, for example, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, and the like. , but is not limited thereto. The carrier may be used alone or as a mixture of two or more.
본 발명의 약학적 조성물은 본 발명의 효과를 해치지 않는 범위에서 약학적으로 허용되는 첨가제를 추가로 포함할 수 있다. 본 발명에서 사용될 수 있는 약학적으로 허용되는 첨가제의 종류는 특별히 제한되지 아니하며 이 기술 분야에서 통상적으로 사용되는 첨가제라면 어느 것이든 사용할 수 있다. 상기 첨가제는 예를 들어, 충전제, 결합제, 붕해제, 현탁화제, 용제, 산화방지제, pH 조절제, 습윤제, 감미제 및 보존제를 들 수 있으나, 이에 한정되지는 것은 아니다. 상기 첨가제는 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive in a range that does not impair the effects of the present invention. The types of pharmaceutically acceptable additives that can be used in the present invention are not particularly limited, and any additives commonly used in the art may be used. The additives may include, but are not limited to, fillers, binders, disintegrants, suspending agents, solvents, antioxidants, pH adjusting agents, wetting agents, sweetening agents and preservatives, for example. The above additives may be used alone or in combination of two or more.
본 발명의 약학적 조성물은 경구 투여 또는 비경구 투여를 위한 적합하고 다양한 제형이 될 수 있다. 본 발명에서, 경구 투여용 제형은 예를 들어, 정제, 환제, 분말, 산제, 과립, 펠렛, 캡슐, 트로키(troches), 로젠지(lozenge), 현탁액, 에멀젼, 시럽 및 엘릭시르제 등을 들 수 있으나, 이에 한정되는 것은 아니다. 본 발명에서, 비경구 투여용 제형은 예를 들어, 주사제, 좌제, 호흡기 흡입제, 에어로졸제, 연고, 도포용 분말, 오일, 크림 및 겔 등을 들 수 있으나, 이에 한정되는 것은 아니다.The pharmaceutical composition of the present invention may be in various formulations suitable for oral or parenteral administration. In the present invention, formulations for oral administration include, for example, tablets, pills, powders, powders, granules, pellets, capsules, troches, lozenges, suspensions, emulsions, syrups and elixirs. However, the present invention is not limited thereto. In the present invention, formulations for parenteral administration include, for example, injections, suppositories, respiratory inhalants, aerosols, ointments, powders for application, oils, creams and gels, but are not limited thereto.
본 발명의 약학적 조성물은 목적에 따라 경구 투여하거나 비경구 투여할 수 있다. 본 발명에서, 비경구 투여는 예를 들어, 복강 투여, 직장 투여, 피하 투여, 정맥 투여, 근육 투여, 흉부 투여, 뇌혈관 투여 및 경피 투여 및 모발 투여를 들 수 있고, 조성물을 질환 부위에 도포하거나 분무, 흡입하는 것도 들 수 있으나, 이에 한정되는 것은 아니다. The pharmaceutical composition of the present invention may be administered orally or parenterally, depending on the purpose. In the present invention, parenteral administration includes, for example, intraperitoneal administration, rectal administration, subcutaneous administration, intravenous administration, intramuscular administration, chest administration, cerebrovascular administration and transdermal administration and hair administration, and the composition is applied to the diseased site or spraying or inhaling, but is not limited thereto.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에서, “약학적으로 유효한 양”은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효한 양의 수준은 환자의 상태, 체중, 성별, 연령, 건강상태, 질병의 정도, 약물에 대한 민감도, 투여 시간, 투여 경로, 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학적 조성물의 투여량은 통상의 기술자에 의해 적절하게 선택될 수 있다. 본 발명의 약학적 조성물의 투여량은 중대가리 추출물의 함량을 기준으로 1일 0.1 mg/kg 내지 2,000 mg/kg 일 수 있고, 보다 바람직하게는 1 mg/kg 내지 500 mg/kg 일 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 투여량의 본 발명의 범위를 한정하는 것은 아니다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of an effective amount includes the patient's condition, weight, sex, age, health Condition, severity of disease, sensitivity to drug, administration time, route of administration, rate of excretion, duration of treatment, factors including concomitant drugs and other factors well known in the medical field. The dosage of the pharmaceutical composition of the present invention may be appropriately selected by those skilled in the art. The dosage of the pharmaceutical composition of the present invention may be 0.1 mg/kg to 2,000 mg/kg per day, more preferably 1 mg/kg to 500 mg/kg, based on the content of the extract of the middle head extract. However, the present invention is not limited thereto. In addition, it does not limit the scope of the present invention of the above dosage.
본 발명의 약학적 조성물의 투여는 하루에 한 번 투여할 수도 있고, 수회 나누어 투여할 수도 있으며, 수일에 한 번 투여할 수도 있다. 본 발명의 약학적 조성물의 투여기간은 통상의 기술자가 환자의 상태, 체중, 성별, 연령, 건강상태, 질병의 정도, 약물에 대한 민감도, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소를 고려하여 결정할 수 있다. Administration of the pharmaceutical composition of the present invention may be administered once a day, may be administered in several divided doses, may be administered once every several days. The administration period of the pharmaceutical composition of the present invention is well known to those skilled in the art by those skilled in the art that the patient's condition, weight, sex, age, health condition, degree of disease, sensitivity to drugs, factors including concurrent drugs, and other medical fields are well known. factors can be taken into account.
본 발명의 약학적 조성물은 단독으로, 또는 다른 치료제와 병용하여 투여될 수 있고, 다른 치료제와 동시에 또는 순차적으로 투여될 수 있다. 또한, 본 발명의 약학적 조성물은 수술, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용될 수 있다.The pharmaceutical composition of the present invention may be administered alone or in combination with other therapeutic agents, and may be administered simultaneously or sequentially with other therapeutic agents. In addition, the pharmaceutical composition of the present invention may be used in combination with surgery, hormone therapy, chemotherapy, and methods using biological response modifiers.
조성물의 제조방법Method for preparing the composition
본 발명에 의하면, 수성 용매에 비타민 C, 레몬머틀 추출물 및 풀러렌을 혼합하여 혼합물을 제조하는 단계를 포함하여, 비타민 C를 포함하는 조성물을 제조할 수 있다.According to the present invention, it is possible to prepare a composition containing vitamin C, including the step of preparing a mixture by mixing vitamin C, lemon myrtle extract and fullerene in an aqueous solvent.
본 발명에 일 실시양태에서, (a) 수성 용매에 비타민 C, 레몬머틀 추출물 및 풀러렌을 혼합하여 혼합물을 제조하는 단계, 및 (b) 혼합물과 유지류를 필링 하는 단계를 포함하여, 비타민 C를 포함하는 조성물을 제조할 수 있다.In one embodiment of the present invention, vitamin C comprising the steps of (a) mixing vitamin C, lemon myrtle extract and fullerene in an aqueous solvent to prepare a mixture, and (b) filling the mixture with oils and fats; compositions can be prepared.
본 발명의 제조방법에서, 유지류를 다른 지용성 성분과 혼합한 후, (a) 단계의 혼합물과 함께 필링할 수 있다. 본 발명의 구체적인 실시예에서, 유지류를 토코페롤, 베타-카로틴 또는 이들 모두와 혼합한 후, (a) 단계의 혼합물과 함께 필링할 수 있다.In the production method of the present invention, after mixing the oil and fat with other fat-soluble ingredients, it may be peeled together with the mixture of step (a). In a specific embodiment of the present invention, after the oils and fats are mixed with tocopherol, beta-carotene or both, it may be filled with the mixture of step (a).
<실시예><Example>
이하에서, 본 발명을 구체적인 실시예 및 실험예를 통하여 보다 상세히 설명한다. 그러나 하기 실시예 및 실험예는 본 발명의 이해를 돕기 위하여 제공되는 것일 뿐, 실시예 및 실험예에 의하여 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through specific examples and experimental examples. However, the following Examples and Experimental Examples are provided only to help the understanding of the present invention, and the scope of the present invention is not limited by the Examples and Experimental Examples.
실시예 1 ~ 5 : 비타민 C를 포함하는 화장료 조성물의 제조Examples 1 to 5: Preparation of a cosmetic composition containing vitamin C
정제수, 아스코르브산, 레몬머틀 증류수, 풀러린, 가용화제(폴리글리세릴-10라우레이트, 폴리글리세릴-4라우레이트, 옥틸도데세스-16) 및 점증제(하이드록시에틸셀룰로스)를 아래 [표 1]의 함량으로 혼합하고, 필터링 하였다. 그 후, 필링하여 실시예 1 내지 5의 화장료 조성물을 수득하였다.Purified water, ascorbic acid, lemon myrtle distilled water, fullerene, solubilizers (polyglyceryl-10 laurate, polyglyceryl-4 laurate, octyldodeses-16) and thickening agents (hydroxyethylcellulose) are listed below [Table 1] ] was mixed and filtered. Thereafter, the cosmetic compositions of Examples 1 to 5 were obtained by peeling.
　 실시예1
(w/v %)Example 1
(w/v %) 		실시예2
(w/v %)Example 2
(w/v %) 		실시예3
(w/v %)Example 3
(w/v %) 		실시예4
(w/v %)Example 4
(w/v %) 		실시예5
(w/v %)Example 5
(w/v %)
정제수Purified water to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100
레몬머틀 증류수Lemon Myrtle Distilled Water -- 1010 3030 5050 7070
풀러렌fullerene 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015
아스코르브산ascorbic acid 1515 1515 1515 1515 1515
폴리글리세릴-10라우레이트Polyglyceryl-10 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
폴리글리세릴-4라우레이트Polyglyceryl-4 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
옥틸도데세스-16Octyldodeces-16 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
하이드록시에틸셀룰로오즈hydroxyethyl cellulose 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4
C 18-21 AlkaneC 18-21 Alkane 　 　 　 　 　
토코페롤tocopherol 　 　 　 　 　
베타-카로틴beta-carotene 　 　 　 　 　
실시예 6 ~ 13 : 비타민 C를 포함하는 화장료 조성물의 제조Examples 6-13: Preparation of a cosmetic composition containing vitamin C
정제수, 아스코르브산, 레몬머틀 증류수, 풀러린, 가용화제(폴리글리세릴-10라우레이트, 폴리글리세릴-4라우레이트, 옥틸도데세스-16) 및 점증제(하이드록시에틸셀룰로스)를 아래 [표 2]의 함량으로 혼합하였다(제1 혼합물). 또한, C 18-21알칸, 토코페롤 및 베타-카로틴을 [표 2]의 함량으로 혼합하였다(제2 혼합물). 그 후, 제1 혼합물과 제2 혼합물을 필링하여 실시예 6 내지 13의 화장료 조성물을 수득하였다.Purified water, ascorbic acid, distilled lemon myrtle water, fullerene, solubilizers (polyglyceryl-10 laurate, polyglyceryl-4 laurate, octyldodeses-16) and thickening agents (hydroxyethylcellulose) are listed below [Table 2] ] (first mixture). In addition, C 18-21 alkane, tocopherol and beta-carotene were mixed in the content of [Table 2] (second mixture). Thereafter, the cosmetic compositions of Examples 6 to 13 were obtained by peeling the first mixture and the second mixture.
　 실시예6
(w/v %)Example 6
(w/v %) 		실시예7
(w/v %)Example 7
(w/v %) 		실시예8
(w/v %)Example 8
(w/v %) 		실시예9
(w/v %)Example 9
(w/v %) 		실시예
10
(w/v %)Example
10
(w/v %) 		실시예
11
(w/v %)Example
11
(w/v %) 		실시예
12
(w/v %)Example
12
(w/v %) 		실시예
13
(w/v %)Example
13
(w/v %)
정제수Purified water to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100
레몬머틀 증류수Lemon Myrtle Distilled Water 5050 5050 5050 5050 5050 5050 5050 5050
풀러렌fullerene 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015
아스코르브산ascorbic acid 1515 1515 1515 1515 1515 1010 1414 1818
폴리글리세릴-10라우레이트Polyglyceryl-10 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
폴리글리세릴-4라우레이트Polyglyceryl-4 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
옥틸도데세스-16Octyldodeces-16 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
하이드록시에틸셀룰로오즈hydroxyethyl cellulose 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4
C 18-21 AlkaneC 18-21 Alkane 1One 55 1010 1515 2020 1One 1One 1One
토코페롤tocopherol 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
베타-카로틴beta-carotene 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
실시예 14 ~ 21 : 비타민 C를 포함하는 화장료 조성물의 제조Examples 14 to 21: Preparation of a cosmetic composition containing vitamin C
실시예 6 ~ 13과 동일한 방법으로 실시예 14 ~ 21을 [표 3]에 기재된 함량에 따라 제조하였다.Examples 14 to 21 were prepared according to the contents described in [Table 3] in the same manner as in Examples 6 to 13.
실시예
14
(w/v %)Example
14
(w/v %) 		실시예
15
(w/v %)Example
15
(w/v %) 		실시예
16
(w/v %)Example
16
(w/v %) 		실시예
17
(w/v %)Example
17
(w/v %) 		실시예
18
(w/v %)Example
18
(w/v %) 		실시예
19
(w/v %)Example
19
(w/v %) 		실시예
20
(w/v %)Example
20
(w/v %) 		실시예21
(w/v %)Example 21
(w/v %)
정제수Purified water to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100
레몬머틀 증류수Lemon Myrtle Distilled Water 5050 5050 5050 5050 5050 5050 5050 5050
풀러렌fullerene 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015
아스코르브산ascorbic acid 1515 1515 1515 1515 1515 1010 1414 1818
폴리글리세릴-10라우레이트Polyglyceryl-10 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
폴리글리세릴-4라우레이트Polyglyceryl-4 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
옥틸도데세스-16Octyldodeces-16 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
하이드록시에틸셀룰로오즈hydroxyethyl cellulose 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4
실리콘silicon 1One 55 1010 1515 2020 1One 1One 1One
토코페롤tocopherol 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
베타-카로틴beta-carotene 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
실시예 22 ~ 29 :Examples 22-29: 비타민 C를 포함하는 화장료 조성물의 제조Preparation of a cosmetic composition containing vitamin C
실시예 6 ~ 13과 동일한 방법으로 실시예 22 ~ 29를 [표 4]에 기재된 함량에 따라 제조하였다.Examples 22 to 29 were prepared according to the contents described in [Table 4] in the same manner as in Examples 6 to 13.
실시예
22
(w/v %)Example
22
(w/v %) 		실시예
23
(w/v %)Example
23
(w/v %) 		실시예
24
(w/v %)Example
24
(w/v %) 		실시예
25
(w/v %)Example
25
(w/v %) 		실시예
26
(w/v %)Example
26
(w/v %) 		실시예
27
(w/v %)Example
27
(w/v %) 		실시예
28
(w/v %)Example
28
(w/v %) 		실시예29
(w/v %)Example 29
(w/v %)
정제수Purified water to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100 to.100to.100
레몬머틀 증류수Lemon Myrtle Distilled Water 5050 5050 5050 5050 5050 5050 5050 5050
풀러렌fullerene 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015 0.000150.00015
아스코르브산ascorbic acid 1515 1515 1515 1515 1515 1010 1414 1818
폴리글리세릴-10라우레이트Polyglyceryl-10 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
폴리글리세릴-4라우레이트Polyglyceryl-4 Laurate 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
옥틸도데세스-16Octyldodeces-16 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15 0.150.15
하이드록시에틸셀룰로오즈hydroxyethyl cellulose 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4 0.40.4
아나토씨오일annatto oil 1One 55 1010 1515 2020 1One 1One 1One
토코페롤tocopherol 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
베타-카로틴beta-carotene 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
실시예 30 ~ 37 :Examples 30-37: 비타민 C를 포함하는 화장료 조성물의 제조Preparation of a cosmetic composition containing vitamin C
실시예 6 ~ 13과 동일한 방법으로 실시예 30 ~ 37을 [표 5]에 기재된 함량에 따라 제조하였다.Examples 30 to 37 were prepared according to the contents described in [Table 5] in the same manner as in Examples 6 to 13.
　 비교예1
(w/v %)Comparative Example 1
(w/v %) 		비교예2
(w/v %)Comparative Example 2
(w/v %) 		비교예3
(w/v %)Comparative Example 3
(w/v %) 		비교예4
(w/v %)Comparative Example 4
(w/v %)
정제수Purified water to.100to.100 to.100to.100 to.100to.100 to.100to.100
레몬머틀 증류수Lemon Myrtle Distilled Water -- 7070 5050 --
풀러렌fullerene -- -- -- --
아스코르브산ascorbic acid 1515 1515 1515 1515
폴리글리세릴-10라우레이트Polyglyceryl-10 Laurate 0.150.15 0.150.15 0.150.15 0.150.15
폴리글리세릴-4라우레이트Polyglyceryl-4 Laurate 0.150.15 0.150.15 0.150.15 0.150.15
옥틸도데세스-16Octyldodeces-16 0.150.15 0.150.15 0.150.15 0.150.15
하이드록시에틸셀룰로오즈hydroxyethyl cellulose 0.40.4 0.40.4 0.40.4 0.40.4
C 18-21 AlkaneC 18-21 Alkane 　-- 　-- 1010 1010
토코페롤tocopherol 　-- 　-- 0.10.1 0.10.1
베타-카로틴beta-carotene 　-- 　-- 0.10.1 0.10.1
<비교예><Comparative example>
비교예 1 및 2는 실시예 1 ~ 5와 동일한 방법으로, 비교예 3 및 4는 실시예 6 ~ 13과 동일한 방법으로, 하기 [표 6]에 기재된 함량에 따라 제조하였다.Comparative Examples 1 and 2 were prepared in the same manner as in Examples 1 to 5, and Comparative Examples 3 and 4 in the same manner as in Examples 6 to 13, according to the contents described in Table 6 below.
　 비교예1
(w/v %)Comparative Example 1
(w/v %) 		비교예2
(w/v %)Comparative Example 2
(w/v %) 		비교예3
(w/v %)Comparative Example 3
(w/v %) 		비교예4
(w/v %)Comparative Example 4
(w/v %)
정제수Purified water to.100to.100 to.100to.100 to.100to.100 to.100to.100
레몬머틀 증류수Lemon Myrtle Distilled Water -- 7070 5050 --
풀러렌fullerene -- -- -- --
아스코르브산ascorbic acid 1515 1515 1515 1515
폴리글리세릴-10라우레이트Polyglyceryl-10 Laurate 0.150.15 0.150.15 0.150.15 0.150.15
폴리글리세릴-4라우레이트Polyglyceryl-4 Laurate 0.150.15 0.150.15 0.150.15 0.150.15
옥틸도데세스-16Octyldodeces-16 0.150.15 0.150.15 0.150.15 0.150.15
하이드록시에틸셀룰로오즈hydroxyethyl cellulose 0.40.4 0.40.4 0.40.4 0.40.4
C 18-21 AlkaneC 18-21 Alkane 　-- 　-- 1010 1010
토코페롤tocopherol 　-- 　-- 0.10.1 0.10.1
베타-카로틴beta-carotene 　-- 　-- 0.10.1 0.10.1
실험예 1 : 본 발명의 화장료 조성물의 비타민 C 안정성 평가Experimental Example 1: Vitamin C stability evaluation of the cosmetic composition of the present invention
실험예 1 - 1 : 저온 및 실온에서의 안정성 평가Experimental Example 1 - 1: Stability evaluation at low temperature and room temperature
상기 표 1 내지 표 6에 기재된 조성으로 실시예 및 비교예를 제조한 후, 비타민 C의 초기 역가를 100으로 하고, 1개월 후의 바타민 C 역가를 5℃ 및 25℃에서 측정하였다.After preparing Examples and Comparative Examples with the compositions shown in Tables 1 to 6, the initial titer of vitamin C was 100, and the titer of vitamin C after 1 month was measured at 5°C and 25°C.
실험 결과는 하기 표 7 내지 9와 같다. 레몬머틀 추출물, 풀러렌 또는 유지류를 포함하는 경우 안정하였으나, 포함하지 않는 경우 안정성이 확보되지 않음이 확인되었다.The experimental results are shown in Tables 7 to 9 below. When lemon myrtle extract, fullerene, or oils and fats were included, it was stable, but it was confirmed that stability was not ensured when not included.
실시예1Example 1 실시예2Example 2 실시예3Example 3 실시예4Example 4 실시예5Example 5 실시예6Example 6 실시예7Example 7
초기Early 100%100% 100%100% 100%100% 100%100% 100%100% 100%100% 100%100%
1달 후1 month later 5℃ 5℃ 98.20%98.20% 97.10%97.10% 98.10%98.10% 97.20%97.20% 98.20%98.20% 98.398.3 97.597.5
25℃25℃ 95.20%95.20% 96.50%96.50% 97.30%97.30% 97.90%97.90% 95.20%95.20% 97.497.4 98.898.8
실시예8Example 8 실시예9Example 9 실시예10Example 10 실시예11Example 11 실시예12Example 12 실시예13Example 13
초기Early 100%100% 100%100% 100%100% 100%100% 100%100% 100%100%
1달 후1 month later 5℃5℃ 98.498.4 99.299.2 94.594.5 94.894.8 93.493.4 94.194.1
25℃25℃ 97.697.6 98.898.8 96.896.8 93.793.7 92.192.1 95.495.4
비교예1Comparative Example 1 비교예2Comparative Example 2 비교예3Comparative Example 3 비교예4Comparative Example 4
초기Early 100%100% 100%100% 100%100% 100%100%
1달 후1 month later 5℃5℃ 88..5%88.5% 92.80%92.80% 87.587.5 84.284.2
25℃25℃ 65.10%65.10% 75.20%75.20% 94.494.4 90.290.2
실험예 1 - 2 : 고온에서의 안정성 평가Experimental Examples 1 - 2: Evaluation of stability at high temperature
상기 표 1 내지 표 6에 기재된 조성으로 실시예 및 비교예를 제조한 후, 비타민 C의 초기 역가를 100으로 하고, 1개월 후의 바타민 C 역가를 40℃에서 측정하였다.After preparing Examples and Comparative Examples with the compositions shown in Tables 1 to 6, the initial titer of vitamin C was 100, and the titer of vitamin C after 1 month was measured at 40°C.
실험 결과는 하기 표 10 및 11과 같다. 레몬머틀 추출물, 풀러렌 또는 유지류를 포함하는 경우 안정하였으나, 포함하지 않는 경우 안정성이 확보되지 않음이 확인되었다.The experimental results are shown in Tables 10 and 11 below. When lemon myrtle extract, fullerene, or oils and fats were included, it was stable, but it was confirmed that stability was not ensured when not included.
실시예6Example 6 실시예7Example 7 실시예8Example 8 실시예9Example 9 실시예10Example 10 실시예11Example 11 실시예12Example 12 실시예13Example 13
초기Early 100%100% 100%100% 100%100% 100%100% 100%100% 100%100% 100%100% 100%100%
1달 후1 month later 40℃40℃ 93.4%93.4% 91.1%91.1% 92.4%92.4% 94.4%94.4% 90.8%90.8% 93.6%93.6% 94.6%94.6% 92.5%92.5%
비교예1Comparative Example 1 비교예2Comparative Example 2 비교예3Comparative Example 3 비교예4Comparative Example 4
초기Early 100%100% 100%100% 100%100% 100%100%
1달 후1 month later 40℃ 40℃ 50.5%50.5% 61.5%61.5% 68.8%68.8% 64.8%64.8%
실험예 2 : 본 발명의 화장료 조성물의 피부자극 시험Experimental Example 2: Skin irritation test of the cosmetic composition of the present invention
(1) 피부반응 육안평가(1) Visual evaluation of skin reaction
식품의약품안전처 기능성 화장품 심사에 관한 규정(2015-14, 2015.03.25) 및 PCPC (Personal Care Products Council) 2014 Safety Evaluation Guideline에 근거하여, 총 32명의 지원자를 대상으로 시험을 진행하였다. 피부과 전문의 검사를 통해 시험에 적합하지 않은 피부상태를 가지고 있지 않다고 판단됨 사람만을 지원자로 선정하였다.Based on the Regulations on the Review of Functional Cosmetics of the Ministry of Food and Drug Safety (2015-14, 2015.03.25) and the Personal Care Products Council (PCPC) 2014 Safety Evaluation Guideline, a total of 32 applicants were tested. Only those who did not have skin conditions that were not suitable for the test were selected as volunteers through the dermatologist's examination.
1차 방문에서, 시험부위를 70% 에탄올로 닦아내고 건조시킨 후, 피험자의 등에 실시예 11, 실시예 12 또는 실시예 13의 화장료 조성물 15㎕를 Finn chamber에 도포 후 플라스터로 고정하였다. 2차 방문(1차 방문으로부터 24시간 후)에서, 패치를 제거하고 30분 경과 뒤 시험부위의 피부반응을 피부과 전문의가 육안으로 판정하였다. 3차 방문(1차 방문으로부터 48시간 후) 및 4차 방문(1차 방문으로부터 72시간 후)에서도 시험부위의 피부반응을 피부과 전문의가 육안으로 판정하였다.At the first visit, after wiping the test site with 70% ethanol and drying, 15 μl of the cosmetic composition of Example 11, Example 12 or Example 13 was applied to the back of the subject in a Finn chamber and fixed with plaster. At the second visit (24 hours after the first visit), the skin reaction of the test site was visually assessed by a dermatologist 30 minutes after the patch was removed. At the 3rd visit (48 hours after the 1st visit) and the 4th (72 hours after the 1st visit), the skin reaction of the test site was visually evaluated by a dermatologist.
피부반응 육안평가는 국제접촉피부염연구회 (ICDRG, International contact dermatitis research group)의 판정기준과 미국화장품협회 (PCPC, Personal Care Products Council)의 안전성 평가 가이드라인을 응용한 다음 기준 표 12에 따라 평가하였다.Skin reaction visual evaluation was evaluated according to the criteria Table 12 after applying the criteria of the International Contact Dermatitis Research Group (ICDRG) and the safety evaluation guidelines of the Personal Care Products Council (PCPC).
자극 점수stimulus score 판정 기준Criteria
0(-)0(-) 염증반응 없음, 보통 피부(No signs of inflammation, normal skin)No signs of inflammation, normal skin
0.5(±)0.5 (±) 의심되거나, 또는 약간의 반응(Doubtful or slight reaction)Doubtful or slight reaction
1(+)1(+) 약간의 홍반(Slight erythema)Slight erythema
2(++)2(++) 보통의 홍반(부종, 구진 동반 또는 비동반)(Moderate erythema with or without partial edema or papules)Moderate erythema with or without partial edema or papules
3(+++)3 (+++) 확산된 부종을 동반한 보통의 홍반(Moderate erythema with diffuse edema)Moderate erythema with diffuse edema
4(++++)4 (++++) 수포를 동반한 확산된 부종을 동반한 중증도 홍반(Intense erythema with diffuse edema with vesicles)Intense erythema with diffuse edema with vesicles
(2) 분석 결과 2차 방문, 3차 방문 및 4차 방문에서 판정된 피험자들의 점수를 하기 식 1에 따라 계산하여 자극지수를 산출하였다.(2) Result of analysis The stimulation index was calculated by calculating the scores of the subjects determined at the 2nd, 3rd and 4th visits according to Equation 1 below.
[식 1][Equation 1]
Figure PCTKR2020014311-appb-img-000003
Figure PCTKR2020014311-appb-img-000003
평균 자극 지수를 산출한 후 Draize Dermal Classification System 및 EPA (Environmental Protection Agency) Standard Procedure Dermal Classification System을 응용한 다음 표 13의 결과 판정표에 따라 자극성의 정도를 판정하였다.After calculating the average irritation index, the Draize Dermal Classification System and EPA (Environmental Protection Agency) Standard Procedure Dermal Classification System were applied, and the degree of irritation was determined according to the result judgment table in Table 13.
자극 지수stimulus index 자극성 평가Irritation Assessment
0≤ <0.020≤ <0.02 무자극 (no irritancy)no irritancy
0.02≤ <0.250.02≤ <0.25 저자극 (low irritancy)low irritancy
0.25≤ <10.25≤ <1 경자극 (slight irritancy)light irritancy
1≤ <2.51≤ <2.5 중자극 (moderate irritancy)moderate irritancy
2.5≤2.5≤ 강자극 (severe irritancy)severe irritancy
(3) 분석 결과그 결과, 실시예 11의 화장료 조성물은 자극 지수 0.016, 실시에 12의 화장료 조성물은 자극지수 0.021, 실시에 13이 화장료 조성물은 자극지수 0.016으로 산출되어 모두 무자극으로 판정되었다.(3) As a result of the analysis, the cosmetic composition of Example 11 had a stimulation index of 0.016, the cosmetic composition of Example 12 had a stimulation index of 0.021, and the cosmetic composition of Example 13 had a stimulation index of 0.016, and all were determined to be non-irritating.
따라서, 본 발명에 의하면, 피부자극 없이도 안정한 비타민 C 포함 화장료 조성물을 제공할 수 있다.Therefore, according to the present invention, it is possible to provide a stable cosmetic composition containing vitamin C without skin irritation.
실험예 3 : 본 발명의 화장료 조성물의 미백 유효성 평가Experimental Example 3: Evaluation of whitening effectiveness of the cosmetic composition of the present invention
(1) 미백 유효성 평가 시험(1) Whitening efficacy evaluation test
피부 질환을 포함하는 급, 만성 신체 질환이 없고, 안면부에 시험에 적합한 과색소 침착증 부위가 있는 자 11명을 피험자로 선정하였으며, 1차 방문에 앞서, 방문일 12시간 전부터 기초 제품의 사용을 금지시켰다.11 subjects who did not have acute or chronic physical diseases including skin diseases and had hyperpigmentation sites suitable for the test were selected as subjects. Prior to the first visit, the use of basic products was prohibited 12 hours before the visit date. .
1차 방문에서, 실시예 11, 실시예 12 또는 실시예 13의 화장료 조성물을 안면에 적용시켰다. 그 후, VISIA®CR(Canfield, 미국)을 이용하여 안면 사진 촬영을 실시하였다. 안면부의 좌측과 우측 각각 과색소 침착증 병변의 한 곳을 찾아 사진상에 표기하고, Mexameter® MX 18(CK electronic GmbH, 독일)을 이용하여 멜라닌 수치(M-value)를 측정하였다. At visit 1, the cosmetic composition of Example 11, Example 12 or Example 13 was applied to the face. Then, facial pictures were taken using a VISIA®CR (Canfield, USA). One of the hyperpigmented lesions on the left and right sides of the facial area was found and marked on the photograph, and the melanin level (M-value) was measured using Mexameter® MX 18 (CK electronic GmbH, Germany).
2차 방문(1차 방문으로부터 2주 후) 및 3차 방문(1차 방문으로부터 4주 후)에서는, 1차 방문과 마찬가지로 실시예 11, 실시예 12 또는 실시예 13의 화장료 조성물을 적용시켰다. 그 후, VISIA®CR을 이용하여 안면 사진 촬영을 실시하였다. 1차 방문에서 표기한 동일 부위에서, Mexameter® MX 18로 과색소 침착증 병변의 멜라닌 수치를 측정하였다. At visit 2 (two weeks after visit 1) and visit 3 (after 4 weeks from visit 1), the cosmetic composition of Example 11, Example 12 or Example 13 was applied as in the 1st visit. Then, facial photography was performed using VISIA®CR. Melanin levels in hyperpigmented lesions were measured with Mexameter® MX 18 at the same site as indicated at Visit 1.
또한, 피부과 전문의가 이상반응(소양증, 홍반 등의 자극 증상) 유무를 평가하였는데, 시험 기간 동안 특별한 피부 이상 증상은 발생하지 않았다.In addition, a dermatologist evaluated the presence or absence of adverse reactions (irritating symptoms such as pruritus and erythema), and no special skin abnormalities occurred during the test period.
(2) Mexameter를 이용한 과색소 침착증 개선 효과 평가 (2) Evaluation of hyperpigmentation improvement effect using Mexameter
1차 방문, 2차 방문 및 3차 방문에서 측정된 멜라닌 수치를 하기 식 2로 계산하여 과색소 침착증 개선 정도를 산출하였으며, 그 결과를 표 14에 나타내었다.The degree of improvement in hyperpigmentation was calculated by calculating the melanin level measured at the first visit, the second visit and the third visit by Equation 2 below, and the results are shown in Table 14.
[식 2][Equation 2]
Figure PCTKR2020014311-appb-img-000004
Figure PCTKR2020014311-appb-img-000004
구분division 측정 값 [A.U.]Measured value [A.U.] 개선율improvement rate p-valuep-value
실시예 11
사용 부위Example 11
area of use 		시험 전before the exam 164.79164.79 -- <0.001<0.001
2차 방문2nd visit 162.19162.19 1.58%1.58%
3차 방문3rd visit 150.05150.05 8.94%8.94%
실시예 12
사용 부위Example 12
area of use 		시험 전before the exam 163.73163.73 -- <0.001<0.001
2차 방문2nd visit 160.39160.39 2.04%2.04%
3차 방문3rd visit 151.85151.85 7.26%7.26%
실시예 13
사용 부위Example 13
area of use 		시험 전before the exam 166.67166.67 -- <0.001<0.001
2차 방문2nd visit 158.00158.00 5.2%5.2%
3차 방문3rd visit 145.12145.12 12.93%12.93%
위 표에 나타낸 바와 같이, 본 발명의 화장료 조성물은 미백효과가 우수함을 확인할 수 있다. 또한, 아스코르브산 18%에서 가장 좋은 미백효과를 나타내는 있는 것을 확인할 수 있다.이상의 설명으로부터, 본 발명이 속하는 기술분야의 통상의 기술자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해되어야 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형되 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.As shown in the table above, it can be confirmed that the cosmetic composition of the present invention has excellent whitening effect. In addition, it can be seen that 18% of ascorbic acid exhibits the best whitening effect. From the above description, those of ordinary skill in the art to which the present invention pertains can provide other specific forms without changing the technical spirit or essential characteristics of the present invention. It will be understood that it can be implemented as In this regard, the examples described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims described below and their equivalents.

Claims (17)

  1. (i) 비타민 C; 및(i) vitamin C; and
    (ii) 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상의 안정화제(ii) at least one stabilizer selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats
    를 포함하는 화장료 조성물.A cosmetic composition comprising a.
  2. 제1항에 있어서, 피부 미백용인 화장료 조성물.The cosmetic composition according to claim 1, for skin whitening.
  3. 제1항에 있어서, (ii) 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 2종 이상의 안정화제를 포함하는 화장료 조성물.The cosmetic composition according to claim 1, wherein (ii) two or more stabilizers selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats.
  4. 제1항에 있어서, (ii) 레몬머틀 추출물 및 풀러렌을 안정화제로 포함하는 화장료 조성물.The cosmetic composition according to claim 1, comprising (ii) lemon myrtle extract and fullerene as stabilizers.
  5. 제1항에 있어서, (ii) 레몬머틀 추출물, 풀러렌 및 유지류를 안정화제로 포함하는 화장료 조성물.The cosmetic composition according to claim 1, comprising (ii) lemon myrtle extract, fullerene, and oils and fats as stabilizers.
  6. 제1항에 있어서, 비타민 C가 순수한 아스코르브산인 화장료 조성물.The cosmetic composition according to claim 1, wherein the vitamin C is pure ascorbic acid.
  7. 제1항에 있어서, 유지류가 탄화수소, 실리콘, 유용성 비타민 유도체 및 에스터 오일로 이루어진 군에서 선택되는 1종 이상인 화장료 조성물.The cosmetic composition according to claim 1, wherein the oils and fats are at least one selected from the group consisting of hydrocarbons, silicones, oil-soluble vitamin derivatives, and ester oils.
  8. 제9항에 있어서, 탄화수소가 C 18-21 알칸인 화장료 조성물.The cosmetic composition according to claim 9, wherein the hydrocarbon is a C 18-21 alkane.
  9. 제1항에 있어서, 비타민 C의 함량이 30 w/v% 이하인 화장료 조성물.The cosmetic composition according to claim 1, wherein the vitamin C content is 30 w/v% or less.
  10. 제1항에 있어서, 비타민 C의 함량이 1 내지 20 w/v% 인 화장료 조성물.The cosmetic composition according to claim 1, wherein the content of vitamin C is 1 to 20 w/v%.
  11. 제1항에 있어서, 레몬머틀 추출물의 함량이 10 내지 70 w/v%인 화장료 조성물.The cosmetic composition according to claim 1, wherein the content of the lemon myrtle extract is 10 to 70 w/v%.
  12. 제1항에 있어서, 풀러렌의 함량이 1 내지 2 ppm인 화장료 조성물.The cosmetic composition according to claim 1, wherein the fullerene content is 1 to 2 ppm.
  13. 제1항에 있어서, 유지류의 함량이 1 내지 20 w/v% 인 화장료 조성물.The cosmetic composition according to claim 1, wherein the content of oils and fats is 1 to 20 w/v%.
  14. 제1항에 있어서, 피부 미백용 기능성 화장품인 화장료 조성물.The cosmetic composition according to claim 1, which is a functional cosmetic for skin whitening.
  15. (i) 비타민 C; 및(i) vitamin C; and
    (ii) 레몬머틀 추출물, 풀러렌 및 유지류로 이루어진 군에서 선택되는 1종 이상의 안정화제(ii) at least one stabilizer selected from the group consisting of lemon myrtle extract, fullerenes and oils and fats
    를 포함하는 미백용 약학적 조성물.A pharmaceutical composition for whitening comprising a.
  16. 수성 용매에 비타민 C, 레몬머틀 추출물 및 풀러렌을 혼합하여 혼합물을 제조하는 단계를 포함하는 비타민 C 함유 조성물의 제조방법.A method for producing a vitamin C-containing composition comprising the step of preparing a mixture by mixing vitamin C, lemon myrtle extract, and fullerene in an aqueous solvent.
  17. 제15항에 있어서, 유지류가 탄화수소, 실리콘, 유용성 비타민 유도체 및 에스터 오일로 이루어진 군에서 선택되는 1종 이상인 제조방법.The method according to claim 15, wherein the oils and fats are at least one selected from the group consisting of hydrocarbons, silicones, oil-soluble vitamin derivatives, and ester oils.
PCT/KR2020/014311 2019-12-06 2020-10-20 Composition comprising vitamin c WO2021112398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0162095 2019-12-06
KR1020190162095A KR102140652B1 (en) 2019-12-06 2019-12-06 Composition Comprising Vitamin C

Publications (1)

Publication Number Publication Date
WO2021112398A1 true WO2021112398A1 (en) 2021-06-10

Family

ID=72042748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/014311 WO2021112398A1 (en) 2019-12-06 2020-10-20 Composition comprising vitamin c

Country Status (2)

Country Link
KR (1) KR102140652B1 (en)
WO (1) WO2021112398A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115040433A (en) * 2022-07-19 2022-09-13 广东迈高生物科技研究有限公司 Stable whitening antioxidant composition and preparation method thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102140652B1 (en) * 2019-12-06 2020-08-03 (주)이시스코스메틱 Composition Comprising Vitamin C
KR102455132B1 (en) 2020-10-27 2022-10-18 (주)이시스코스메틱 Cosmetic composition containing lemon myrtle extract and its manufacturing method
KR102546787B1 (en) * 2020-11-12 2023-06-23 주식회사 라피끄 Cosmetic composition comprising high concentration of pure vitamin c
KR102379257B1 (en) * 2021-09-29 2022-03-28 코스맥스 주식회사 Oil-dispersion solid cosmetic composition containing ascorbic acid and method for manufacturing thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050019668A (en) * 2003-08-20 2005-03-03 동아제약주식회사 Nonaqueous system emulsion cosmetic composition comprising Vit C
JP2013017467A (en) * 2011-06-15 2013-01-31 Kaneka Corp Citral flavoring agent and method for manufacturing the same
KR20170141991A (en) * 2016-06-16 2017-12-27 주식회사 코리아나화장품 Skin protective cosmetic composition for stabilizing vitamin c containing bergenin and fullerene
KR20190079835A (en) * 2017-12-28 2019-07-08 김주호 Cosmetic composition comprising L-Ascorbic Acid stable to light and high temperature condition
JP2019203033A (en) * 2012-12-27 2019-11-28 株式会社林原 External composition for skin for antiaging, and production method thereof
KR102140652B1 (en) * 2019-12-06 2020-08-03 (주)이시스코스메틱 Composition Comprising Vitamin C

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938969A (en) 1988-11-14 1990-07-03 Milor Scientific, Ltd. Method for the treatment of aging or photo-damaged skin
JP5283873B2 (en) * 2007-08-31 2013-09-04 株式会社カネカ Whitening composition
KR101927655B1 (en) * 2018-03-16 2018-12-10 김정숙 Method for Producing Micro-Needle Patch including Vitamin and the Micro-Needle Patch including the Vitamin
KR102022900B1 (en) * 2019-02-14 2019-09-20 (주)아모레퍼시픽 An additive composition for improving feeling of using cosmetics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050019668A (en) * 2003-08-20 2005-03-03 동아제약주식회사 Nonaqueous system emulsion cosmetic composition comprising Vit C
JP2013017467A (en) * 2011-06-15 2013-01-31 Kaneka Corp Citral flavoring agent and method for manufacturing the same
JP2019203033A (en) * 2012-12-27 2019-11-28 株式会社林原 External composition for skin for antiaging, and production method thereof
KR20170141991A (en) * 2016-06-16 2017-12-27 주식회사 코리아나화장품 Skin protective cosmetic composition for stabilizing vitamin c containing bergenin and fullerene
KR20190079835A (en) * 2017-12-28 2019-07-08 김주호 Cosmetic composition comprising L-Ascorbic Acid stable to light and high temperature condition
KR102140652B1 (en) * 2019-12-06 2020-08-03 (주)이시스코스메틱 Composition Comprising Vitamin C

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115040433A (en) * 2022-07-19 2022-09-13 广东迈高生物科技研究有限公司 Stable whitening antioxidant composition and preparation method thereof
CN115040433B (en) * 2022-07-19 2023-09-08 博贤实业(广东)有限公司 Stable whitening and antioxidant composition and preparation method thereof

Also Published As

Publication number Publication date
KR102140652B1 (en) 2020-08-03

Similar Documents

Publication Publication Date Title
WO2021112398A1 (en) Composition comprising vitamin c
WO2016167527A1 (en) Cosmetic composition for skin regeneration and pharmaceutical composition for wound treatment, containing sinapic acid, which is marker component of cynanchum atratum extracts, or cynanchum atratum extracts containing same
WO2010016683A9 (en) Composition for the prevention and treatment of alopecia or for hair growth
KR20190134652A (en) Skin treatment method
WO2015002393A1 (en) Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof
WO2018174453A1 (en) Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis
WO2019027132A1 (en) Composition for preventing or treating scars
WO2018124572A1 (en) Silicon resin composition, preparation method therefor, and scar treatment agent including same
WO2012020989A9 (en) Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
WO2012173382A2 (en) Skin composition for external use containing tanshinone ii a as active ingredient
WO2024010255A1 (en) Pharmaceutical composition for preventing or treating hair loss, containing connarus semidecandrus jack. extract
WO2020111621A1 (en) Composition for inhibiting hair loss or skin inflammation
WO2023022540A1 (en) Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as active ingredient
WO2017119535A1 (en) Anti-aging composition comprising carnosine, soy peptide, and andrographis paniculata extract
KR101623375B1 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
WO2016056780A1 (en) Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract
WO2019139403A1 (en) Composition containing sericin, torilis japonica extract, and viscum album extract for skin generation, skin soothing, or wound healing
KR20140000882A (en) Composition for moisturizing skin comprising ginseng oil as active ingredient
WO2017142368A2 (en) Composition for preventing and treating allergic or inflammatory skin disease
WO2020256380A1 (en) Composition for skin whitening, comprising carvone or salt thereof as active ingredient
WO2012173383A2 (en) Skin composition for external use containing cryptotanshinone as active ingredient
WO2020256381A1 (en) Skin whitening composition comprising octadecene or salt thereof as active ingredient
WO2019031655A1 (en) Composition comprising thymol as effective ingredient for preventing or treating skin wrinkle or atopic dermatitis
WO2020036266A1 (en) Nanoliposome preparation method using horse oil and nanodiamonds and composition thereof
WO2021075929A1 (en) Composition, comprising an artemisia princeps leaf extract, for alleviation of skin damage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20896492

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20896492

Country of ref document: EP

Kind code of ref document: A1